

RESEARCH

Open Access

# Effect of thromboelastography (TEG<sup>®</sup>) and rotational thromboelastometry (ROTEM<sup>®</sup>) on diagnosis of coagulopathy, transfusion guidance and mortality in trauma: descriptive systematic review

Luis Teodoro Da Luz<sup>1</sup>, Bartolomeu Nascimento<sup>2</sup>, Ajith Kumar Shankarakutty<sup>3</sup>, Sandro Rizoli<sup>4</sup> and Neill KJ Adhikari<sup>1\*</sup>

## Abstract

**Introduction:** The understanding of coagulopathies in trauma has increased interest in thromboelastography (TEG<sup>®</sup>) and thromboelastometry (ROTEM<sup>®</sup>), which promptly evaluate the entire clotting process and may guide blood product therapy. Our objective was to review the evidence for their role in diagnosing early coagulopathies, guiding blood transfusion, and reducing mortality in injured patients.

**Methods:** We considered observational studies and randomized controlled trials (MEDLINE, EMBASE, and Cochrane databases) to February 2014 that examined TEG<sup>®</sup>/ROTEM<sup>®</sup> in adult trauma patients. We extracted data on demographics, diagnosis of early coagulopathies, blood transfusion, and mortality. We assessed methodologic quality by using the Newcastle-Ottawa scale (NOS) for observational studies and QUADAS-2 tool for diagnostic accuracy studies.

**Results:** Fifty-five studies (12,489 patients) met inclusion criteria, including 38 prospective cohort studies, 15 retrospective cohort studies, two before-after studies, and no randomized trials. Methodologic quality was moderate (mean NOS score, 6.07; standard deviation, 0.49). With QUADAS-2, only three of 47 studies (6.4%) had a low risk of bias in all domains (patient selection, index test, reference standard and flow and timing); 37 of 47 studies (78.8%) had low concerns regarding applicability. Studies investigated TEG<sup>®</sup>/ROTEM<sup>®</sup> for diagnosis of early coagulopathies ( $n = 40$ ) or for associations with blood-product transfusion ( $n = 25$ ) or mortality ( $n = 24$ ). Most ( $n = 52$ ) were single-center studies. Techniques examined included rapid TEG<sup>®</sup> ( $n = 12$ ), ROTEM<sup>®</sup> ( $n = 18$ ), TEG<sup>®</sup> ( $n = 23$ ), or both TEG<sup>®</sup> and rapid TEG<sup>®</sup> ( $n = 2$ ). Many TEG<sup>®</sup>/ROTEM<sup>®</sup> measurements were associated with early coagulopathies, including some (hypercoagulability, hyperfibrinolysis, platelet dysfunction) not assessed by routine screening coagulation tests. Standard measures of diagnostic accuracy were inconsistently reported. Many abnormalities predicted the need for massive transfusion and death, but predictive performance was not consistently superior to routine tests. One observational study suggested that a ROTEM<sup>®</sup>-based transfusion algorithm reduced blood-product transfusion, but TEG<sup>®</sup>/ROTEM<sup>®</sup>-based resuscitation was not associated with lower mortality in most studies.

**Conclusions:** Limited evidence from observational data suggest that TEG<sup>®</sup>/ROTEM<sup>®</sup> tests diagnose early trauma coagulopathy and may predict blood-product transfusion and mortality in trauma. Effects on blood-product transfusion, mortality, and other patient-important outcomes remain unproven in randomized trials.

\* Correspondence: [neill.adhikari@utoronto.ca](mailto:neill.adhikari@utoronto.ca)

<sup>1</sup>Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and University of Toronto, 2075 Bayview Avenue Room D1.08, Toronto, ON M4N 3M5, Canada

Full list of author information is available at the end of the article

## Introduction

The emerging understanding of early coagulopathies and their clinical consequences after severe trauma have created a search for better coagulation assays. Current routine screening coagulation tests (RSCTs), such as activated partial thromboplastin time (aPTT) and prothrombin time (PT), have limited utility to diagnose early trauma coagulopathies and direct their treatment. Neither test predicts the extent of bleeding in critically ill or trauma patients [1], and a recent systematic review concluded that they are inappropriate for trauma [2]. The cell-based understanding of hemostasis [3], emphasizing tissue factor (TF) as the initiator of coagulation and the role of platelets, has challenged the clotting cascade concept that underlies RSCTs. The cell-based model and the need for shorter turnaround time (TAT) for tests to guide transfusion in bleeding trauma patients have propelled interest in thromboelastography (TEG<sup>®</sup>; Hemoscope Corporation, Niles, IL, USA) and thromboelastometry (ROTEM<sup>®</sup>; Tem International GmbH).

TEG<sup>®</sup> and ROTEM<sup>®</sup> are based on the principle that the result of the hemostatic process is a clot whose physical properties determine patients' hemostatic status. These tests provide global information on the dynamics of clot development, stabilization, and dissolution, reflecting *in vivo* hemostasis, and assess both thrombosis and fibrinolysis [4]. The additional information from TEG<sup>®</sup>/ROTEM<sup>®</sup> is based on their performance in whole blood [4], whereas RSCTs are performed in plasma, without the cellular components of platelets and tissue-bearing cells.

By systematically searching for relevant studies, we sought to evaluate the evidence that the use of TEG<sup>®</sup> and ROTEM<sup>®</sup> in adult traumatically injured patients (a) diagnoses trauma coagulopathies on admission to hospital, (b) guides transfusion, and (c) reduces mortality.

## Materials and methods

This descriptive systematic review was reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [5].

### Information sources and search technique

With the assistance of an experienced librarian, we searched MEDLINE (1946 to February 2014), EMBASE (1947 to February 2014), and Cochrane Controlled Trials Register (from inception to February 2014) to identify studies of thromboelastography and thromboelastometry in trauma. We used a sensitive search strategy combining MeSH headings and the key words "thromboelastography" AND "trauma," "thromboelastometry" AND "trauma," "thromboelastography" AND injury," "thromboelastometry" AND "injury," TEG<sup>®</sup> AND "trauma," TEG<sup>®</sup> AND "injury," ROTEM<sup>®</sup> AND "trauma," and ROTEM<sup>®</sup>

AND "injury." Search terms were defined *a priori* and by reviewing the MeSH terms of articles identified in preliminary literature searches. Two authors (LTL, AKS) independently reviewed the abstracts of all articles identified by the literature search and selected articles for detailed review if either reviewer considered them potentially relevant. We also searched the bibliographies of all articles selected for detailed review and all relevant published reviews to find any other studies potentially eligible for inclusion. We did not search conference proceedings. No language restrictions were imposed; we translated two studies in Spanish and Italian and engaged a medical student to translate one Chinese study that was ultimately excluded. Details of the search strategies are in Additional file 1.

### Eligibility criteria and study selection

Studies were eligible for inclusion if they were observational studies or randomized controlled trials (RCTs) that evaluated TEG<sup>®</sup>/ROTEM<sup>®</sup> in adult trauma patients and reported outcomes related to diagnosis of coagulopathies (hypocoagulation, hypercoagulation, platelet dysfunction, hyperfibrinolysis (HF), TAT), transfusion management (prediction of massive transfusion (MT), and transfusion guidance), or mortality (prediction and reduction). Studies were excluded if they enrolled only burn patients or enrolled patients in other surgical specialties, or were case reports or case series. Two independent reviewers (LTL, AKS) reviewed all full-text versions of all potentially eligible studies. Agreement between reviewers was assessed by using the Cohen  $\kappa$  [6]. In case of disagreement, consensus was reached by discussion with a third author (BN, NKJA).

### Data abstraction and analysis

We abstracted data from included studies on study objective, setting and study design, patient selection, clinical and demographic characteristics, TEG<sup>®</sup>/ROTEM<sup>®</sup> technique, RSCT technique, presence of comparison group, blood-product transfusion, and mortality. Two authors (LTL, AKS) independently assessed study methodology based on the Newcastle-Ottawa Scale for cohort studies [7] and QUADAS-2 [8] for quality assessment of diagnostic accuracy studies. For studies that did not report diagnostic accuracy, we supplemented the Newcastle-Ottawa scale by assessing the description of TEG<sup>®</sup>/ROTEM<sup>®</sup> performance. In applying the Newcastle-Ottawa scale, we considered management by TEG<sup>®</sup>/ROTEM<sup>®</sup> to be the relevant exposure and a nonexposed cohort to be one that was managed without TEG<sup>®</sup>/ROTEM<sup>®</sup>. We considered the following outcomes: (a) diagnostic performance of TEG<sup>®</sup>/ROTEM<sup>®</sup> parameters compared with RSCT (PT, aPTT, INR, platelet count, fibrinogen) for early coagulopathies, (b) utilization of blood products red blood cells (RBCs),

fresh frozen plasma (FFP), platelets concentrate (PLT), fibrinogen concentrate (FC), cryoprecipitate, prothrombin complex concentrate (PCC), and (c) mortality. Because of clinical and methodologic heterogeneity among studies, we anticipated reporting results qualitatively instead of conducting meta-analyses.

## Results

The electronic search identified 1,352 potentially relevant studies. After evaluating 82 full-text manuscripts, 55 met inclusion criteria (Figure 1). An excellent agreement was reached between the reviewers for study inclusion ( $\kappa = 0.82$ ). References for the excluded studies are in Additional file 1.

### Study characteristics

All 55 studies were observational (Table 1). Forty studies [9-48] addressed the use of TEG<sup>®</sup>/ROTEM<sup>®</sup> in diagnosing early coagulopathies; 25 studies [9,15,16,22,23,25,26,29,31,32,35-37,41,45,47-56] examined associations with transfusion; and 24 studies [14,16,21,23,29,32,33,36-38,40,45,47,48,51,54,56-63] examined associations with mortality. Only three [40,41,61] were conducted in multiple centers. Thirty-eight studies were prospective cohorts [9-14,16,17,19,20,24-28,30,32,33,36,38,40-48,50,52,53,55-58,61,62], two were before-after [37,63], and 15 were retrospective cohorts [15,18,21-23,29,31,34,35,39,49,51,54,

59,60]. The techniques used for TEG<sup>®</sup> and ROTEM<sup>®</sup> varied: in 28 studies [9,11-14,17,20,22,26,28,30,33,38-41,44,45,47,49,50,52-55,58,59,61,63], the tests were done at 37°C; in nine [10,15,16,18,19,21,37,43,57], at the patient's temperature; in 16, there was no description of the temperature [23-25,29,31,32,34-36,42,46,48,51,56,60,62]; and one study performed the test at different temperatures [27]. Rapid TEG<sup>®</sup> (r-TEG<sup>®</sup>), a technique with fresh whole blood using a solution containing TF as the coagulation trigger, was used in 12 studies [17,18,21,25,33-35,37,43,49,52,54]; ROTEM<sup>®</sup>, in 18 studies [12,14,20,22,23,26,28,31,32,38,40,42,50,51,55,58-60]; TEG<sup>®</sup>, in 23 studies [9-11,13,15,16,19,24,27,29,30,36,39,41,44,45,53,56-58,61-63]; and two studies performed TEG<sup>®</sup> and r-TEG<sup>®</sup> [17,46] in the same cohort of patients.


### Demographic data

The 55 studies included 12,489 patients. The mean or median age of the patients ranged from 24 to 74 years (mean of mean or median age across all studies, 40 years). The majority were male (9,858 patients, 78.9%), and the mean injury severity score (ISS) [64] ranged from 9 to 55 (mean of means in all studies, 25.3). Studies included trauma with or without traumatic brain injury (TBI) ( $n = 49$ ), isolated TBI ( $n = 4$ ), and burns with all types of trauma ( $n = 2$ ). The median (interquartile range (IQR)) sample size of the included studies was 87 (52 to 235).

### Methodologic quality

The overall methodologic quality of the studies was moderate (Table 2). Most studies ( $n = 36$ ) included consecutive patients [10,12-14,16,19,21-27,30-35,37-41,45,46,50-52,54-56,58-60,63]. Fifty-two (94.5%) studies were not controlled [9-11,13-36,38-50,52-62]. The three (5.5%) controlled studies [37,51,63] had comparable control groups managed without TEG<sup>®</sup>/ROTEM<sup>®</sup>. Eleven (20%) studies used healthy [12,13,19,27,41,42,44,61] or other hospitalized trauma [24,32,60] controls to examine associations between TEG<sup>®</sup>/ROTEM<sup>®</sup> abnormalities and outcomes. Nearly all ( $n = 53$ , 96.4%) studies had adequate follow-up. The mean Newcastle-Ottawa score ( $n = 55$  studies) was 6.07 (SD, 0.49; possible range, 1 to 9).

We assessed 47 studies of diagnostic accuracy by using QUADAS-2 (Table 3). Considering the domains of patient selection, index test, reference standard, and flow and timing, only three studies (6.4%) [32,37,39] had low risk of bias in all; 24 (51.1%) [10,16,21-26,30,31,33-35,38,40,44,45,47,50,52,54,55,58,62] had low and unclear risks; and 20 (42.5%) [9,11-15,17-20,29,36,42,48,49,53,57,59-61] had high risk of bias in at least one domain. In the applicability section, 37 studies (78.8%) [9-11,16-18,21-26,29-40,44,45,47,48,50,52-55,57-59,62] had low concerns, and 10 studies (21.2%) [12-15,19,20,42,49,60,61] had at least one domain with high concern. The remaining eight studies



**Table 1 Characteristics of the studies included in the systematic review**

Reference	Design	Population/Years of enrollment	Patients/ Centers	Age (years)	Male, n (%)	Technique (TEG®/ROTEM®)	Intervention
Kaufmann 1997 [9]	Prospective	ISS 12.3 <sup>b</sup> 1994 - 1995	69/1	40.0 <sup>b</sup>	41 (59.4%)	TEG® - 37°C Whole blood Celite activated	None
Watts 1998 [10]	Prospective	ISS 16.6 <sup>b</sup> 1996 - 1997	112/1	36.4 <sup>b</sup>	76 (68.0%)	TEG® - patient's T Citrate blood recalcified	None
Schreiber 2005 [11]	Prospective	ISS 23.0 <sup>a</sup> Years not reported	65/1	42.0 <sup>b</sup>	45 (69.0%)	TEG® - 37°C Whole blood Kaolin activated	None
Rugeri 2007 [12]	Prospective	ISS 22.0 <sup>a</sup> 2004	88/1	34.0 <sup>b</sup>	68 (77.2%)	ROTEM® - 37°C Citrate blood, recalcified Ellagic acid and TF	None
Nekudov 2007 [13]	Prospective	ISS TBI: 33.0 <sup>a</sup> ISS general: 46.0 <sup>a</sup> 2006	47/1	TBI: 42.0 <sup>a</sup> Trauma: 36.0 <sup>a</sup>	19 (95.0%)	TEG® - 37°C Citrate blood, recalcified Kaolin added	None
Levrat 2008 [14]	Prospective	ISS HF: 38.0 <sup>a</sup> ISS non HF: 20.0 <sup>a</sup> 2004	87/1	HF: 29.0 <sup>a</sup> No HF: 30.0 <sup>a</sup>	HF: 64 (78.0%) No HF: 4 (80.0%)	ROTEM® - 37°C Citrate blood, recalcified Ellagic acid or TF	None
Park 2008 [57]	Prospective	ISS 23.0 <sup>b</sup> 2004-2005	58/1	47.0 <sup>b</sup>	44 (76%)	TEG® - patient's T Citrate blood, recalcified Added TF	None
Plotkin 2008 [15]	Retrospective	ISS 21.0 <sup>b</sup> 2004	44/1	Not reported	Not reported	TEG® - patient's T Fresh blood Celite 1% added	None
Carroll 2009 [16]	Prospective	ISS 20.0 <sup>a</sup> Years not reported	161/1	42.0 <sup>a</sup>	118 (73.0%)	TEG® - patient's T Citrate blood Heparinized for PM	None
Jeger 2009 [17]	Prospective	ISS 29.0 <sup>a</sup> Years not reported	20/1	48.0 <sup>a</sup>	13 (65.0%)	r-TEG® and TEG® - 37°C Fresh blood TF added	None
Kashuk 2009 [49]	Retrospective	ISS 29.0 <sup>a</sup> 2008	44/1	38.9 <sup>b</sup>	32 (69.6%)	r-TEG® - 37°C Citrate and non-citrate r-TEG® solution	None
Kashuk 2009 [18]	Retrospective	ISS Hypercoagulable: 26 <sup>b</sup> ISS Normal: 24.0 <sup>b</sup> Years not reported	152/1	Hypercoagulable: 45.0 <sup>a</sup> Normal group: 38.0 <sup>a</sup>	107 (70.5%)	r-TEG® - patient's T Whole blood Added Kaolin and TF	None

**Table 1 Characteristics of the studies included in the systematic review (Continued)**

Park 2009 [19]	Prospective	ISS burn: 18.1 <sup>b</sup> ISS non burn: 21.7 <sup>b</sup> 2004 – 2005	78/1	Burn: 56.0 <sup>b</sup> Nonburn: 43.0 <sup>b</sup> Controls: 37.3 <sup>b</sup>	Burn: 18 (72.0%) Nonburn: 26 (78.0%) Control: 11 (55.0%)	TEG® - patient's T Fresh blood TF added	None
Schöchl 2009 [58]	Prospective	ISS 42.0 <sup>b</sup> 2003 - 2007	33/1	45.0 <sup>a</sup>	22 (67.0%).	ROTEM® - 37°C Citrated blood, recalcified TF added	None
Doran 2010 [20]	Prospective	ISS MT: 35.0 <sup>a</sup> ISS non MT: 20.0 <sup>a</sup> 2009	25/1	21.0 <sup>a</sup>	25 (100.0%)	ROTEM® - 37°C Citrated blood, recalcified	None
Kashuk 2010 [21]	Retrospective	ISS MT: 32.5 <sup>a</sup> ISS ModT: 29.0 <sup>a</sup> ISS MinT: 34.0 <sup>a</sup> Years not reported	61/1	34.2 <sup>b</sup>	Not reported	r-TEG® - patient's T Fresh whole blood r-TEG® solution	None
Leemann 2010 [22]	Retrospective	ISS 31.1 <sup>b</sup> 2006	53/1	39.6 <sup>b</sup>	40 (75.5%)	ROTEM® - 37°C Citrated blood, recalcified Ellagic acid or TF	None
Schöchl 2010 [59]	Retrospective	ISS 38.0 <sup>b</sup> 2005 - 2009	131/1	46.0 <sup>b</sup>	96 (73.0%)	ROTEM® - 37°C Citrated blood, recalcified Calcium chloride added	ROTEM® FC and PCC guided therapy
Schöchl 2011 [23]	Retrospective	ISS survivors: 20.0 <sup>a</sup> ISS nonsurvivors: 29.0 <sup>a</sup> 2005 - 2010	88/1	47.0 <sup>a</sup>	67 (76.0%)	ROTEM® - T not reported Citrated blood, recalcified TF, Kaolin, Cytochalasin	None
Watters 2010 [24]	Prospective	ISS surgery: 35.3 <sup>b</sup> ISS control: 21.2 <sup>b</sup> Years not reported	80/1	Surgery: 41.1 <sup>b</sup> Controls: 33.7 <sup>b</sup>	59 (73.7%)	TEG® - T not reported No further details reported	None
Cotton 2011 [25]	Prospective	ISS 14.0 <sup>a</sup> 2009 - 2010	272/1	34.0 <sup>a</sup>	201 (74.0%)	r-TEG® - T not reported Citrated blood CaCl <sub>2</sub> , Kaolin and TF added	None
Davenport 2011 [26]	Prospective	ISS 12.0 <sup>a</sup> 2007 - 2009	300/1	33.0 <sup>a</sup>	246 (82.0%)	ROTEM® - 37°C Citrated blood, recalcified TF added	None
Davenport 2011 [50]	Prospective	ISS 29.0 <sup>a</sup> 2007 - 2009	50/1	42.0 <sup>a</sup>	41 (82.0%)	ROTEM® - 37°C Citrated blood, recalcified TF added	None

**Table 1 Characteristics of the studies included in the systematic review (Continued)**

Differding 2011 [27]	Prospective	ISS 20.0 <sup>a</sup>  Years not reported	46/1	Patients: 48.0 <sup>a</sup>  Controls: 38.0 <sup>a</sup>	23 (50.0%)	TEG® - 38, 36, 34, 32°C  Citrated blood, recalcified  Kaolin solution added	None
Jansen 2013 [28]	Prospective	ISS 19.0 <sup>a</sup> 2010	10/1	Not reported	Not reported	ROTEM® - 37°C  Citrated blood, recalcified  TF, Cytochalasin	None
Nystrup 2011 [29]	Retrospective	ISS 21.0 <sup>b</sup>  2006 - 2007	89/1	39.0 <sup>b</sup>	59 (66.0%)	TEG® - T not reported  Citrated blood  No further technical details	None
Ostrowski 2011 [30]	Prospective	ISS 5-36 2010	80/1	48.0 <sup>b</sup>	54 (67.6%)	TEG® - 37°C  Citrated blood  No further details reported	None
Schöchgl 2011 [51]	Retrospective	FC-PCC group: 35.5 <sup>b</sup>  FFP group: 35.2 <sup>b</sup> 2006 - 2009	681/2	FC-PCC: 37.3 <sup>b</sup>  FFP: 39.0 <sup>b</sup>	505 (74.1%)	ROTEM® - T not reported  No technical details reported	PCC and FC guided by ROTEM®. Comparison with standard FFP transfusion
Schöchgl 2011 [31]	Retrospective	MT group: 27.0 <sup>a</sup>  Non MT group: 42.0 <sup>a</sup>  2005 - 2010	323/1	44.0 <sup>a</sup>	255 (78.9%)	ROTEM® - T not reported  Citrated blood, recalcified  Kaolin, TF, Cytochalasin	None
Tauber 2011 [32]	Prospective	ISS 34.0 <sup>a</sup>  2005 - 2008	334/1	43.0 <sup>a</sup>	260 (77.8%)	ROTEM® - T not reported  No further technical details	FFP, PLT, FC and PCC guided by ROTEM®.
Theusinger 2011 [60]	Retrospective	ISS trauma HF: 55 <sup>b</sup>  Non trauma HF: 43 <sup>b</sup> 2008 - 2010	35/1	55.0 <sup>b</sup>	26 (74.2%)	ROTEM® - T not reported  No further technical details	None
Cotton 2012 [33]	Prospective	ISS HF: 25.0 <sup>a</sup>  ISS non HF: 16.0 <sup>a</sup>  2009 - 2010	1996/1	HF group: 29.0 <sup>a</sup>  No HF: 33.0 <sup>a</sup>	HF: 27 (67.0%)  Non HF: 1466 (75.0%)	r-TEG® - 37°C  Citrated blood, recalcified  Kaolin and TF added	None
Cotton 2012 [34]	Retrospective	ISS PE: 31.0 <sup>a</sup>  ISS no PE: 19.0 <sup>a</sup>  2009 - 2011	2067/1	PE: 41.0 <sup>a</sup>  No PE: 33.0 <sup>0a</sup>	PE group: 36 (69.0%)  No PE: 1530 (76%)	r-TEG® - T not reported  Citrated blood  Na Chloride, TF, Kaolin	None

**Table 1 Characteristics of the studies included in the systematic review (Continued)**

Davis 2013 [61]	Prospective	ISS 25.0 <sup>a</sup> Years not reported	50/2	48.5 <sup>a</sup>	36 (72.0%)	TEG <sup>®</sup> . TEG <sup>®</sup> -PM - 37°C Activation solution added Heparinized blood ADP, AA and Kaolin	None
Holcomb 2012 [35]	Retrospective	ISS 17.0 <sup>a</sup> 2009 - 2011	1974/1	33.0 <sup>a</sup>	1480 (75.0%)	r-TEG <sup>®</sup> - T not reported Citratd blood CaCl <sup>2</sup> , kaolin and TF added	None
Ives 2012 [36]	Prospective	ISS dead: 26.4 <sup>a</sup> ISS alive: 14.8 <sup>a</sup> 2010 - 2011	118/1	Dead: 34.8 <sup>b</sup> Alive: 36.7 <sup>b</sup>	91 (77.1%)	TEG <sup>®</sup> , T not reported Citratd blood Kaolin and CaCl <sup>2</sup> added	None
Jeger 2012 [52]	Prospective	ISS 18.0 <sup>b</sup> 2009 - 2010	76/1	49.0 <sup>b</sup>	55 (72.0%)	r-TEG <sup>®</sup> - 37°C TF, Kaolin added Citratd blood, recalcified	Physicians blinded to TEG <sup>®</sup> Transfusion guided clinically and with RSCT results.
Kashuk 2012 [37]	Before and after study	ISS 0–25: 9% ISS 26–35: 29% ISS ≥ 36: 62% Over 7 months Years not reported	68/1	r-TEG <sup>®</sup> : 33.3 <sup>b</sup> TEG <sup>®</sup> : 40.5 <sup>b</sup>	r-TEG <sup>®</sup> : 29 (85.0%) TEG <sup>®</sup> : 25 (74.0%)	r-TEG <sup>®</sup> - patient's T Fresh blood Kaolin, TF, stabilizers added	TEG <sup>®</sup> guided resuscitation implemented and compared with the pre TEG <sup>®</sup> period
Kunio 2012 [62]	Prospective	ISS 21.0 <sup>a</sup> 2010 - 2011	69/1	46.0 <sup>a</sup>	56 (81.2%)	TEG <sup>®</sup> - T not reported Fresh whole blood non Citratd and Kaolin activated	None
Kutcher 2012 [38]	Prospective	ISS 22.0 <sup>b</sup> 2011 - 2012	115/1	40.8 <sup>b</sup>	Not reported	ROTEM <sup>®</sup> - 37°C Citratd whole blood TF and aprotinin added	None
Nascimento 2012 [39]	Retrospective	ISS 26.0 <sup>b</sup> 2007	219/1	39.0 <sup>b</sup>	154 (69.0%)	TEG <sup>®</sup> - 37°C Citratd blood Kaolin, stabilizers added	None
Ostrowski 2012 [53]	Prospective	ISS heparinized: 31.0 <sup>a</sup> ISS non heparin: 17.0 <sup>a</sup> 2010	77/1	Heparin: 74.0 <sup>a</sup> Noneparin: 44.0 <sup>a</sup>	53 (68.8%)	TEG <sup>®</sup> - 37°C Citratd whole blood Kaolin TEG <sup>®</sup> , heparinase TEG <sup>®</sup>	None
Pezold 2012 [54]	Retrospective	ISS 29.0 <sup>b</sup> 2008 - 2010	80/1	34.0 <sup>b</sup>	65 (81.0%)	r- TEG <sup>®</sup> - 37°C Fresh whole blood Kaolin and TF added	None

**Table 1 Characteristics of the studies included in the systematic review (Continued)**

Raza 2013 [55]	Prospective	ISS 10.0 <sup>a</sup> 2007 - 2009	288/1	37.0 <sup>a</sup>	236 (81.9%)	ROTEM® - 37°C Citratd blood, added TF Antifibrinolytic, CaCl <sup>2</sup> or Aprotinin	None
Rourke 2012 [40]	Prospective	ISS 34.0 <sup>a</sup> 2008 - 2010	517/2	36.0 <sup>a</sup>	405 (78.0%)	ROTEM® - 37°C Citratd blood Recalcified	Pre-fixed MTP, including administration of RBC, FFP, PLT, CRYO and FC and ex vivo FC
Wohlauer 2012 [41]	Prospective	ISS 19.0 <sup>b</sup> Years nor reported	51/2	44.0 <sup>b</sup>	32 (63.0%)	TEG® - 37°C Citratd whole blood Kaolin TEG®, AA and ADP TEG®-PM	None
Woolley 2013 [42]	Prospective	ISS not reported 2009	48/1	24.0 <sup>a</sup>	Not reported	ROTEM® - T not reported Citratd blood, recalcified Added TF, Cytochalasin	None
Chapman 2013 [43]	Prospective	Non TEG®: 18.3 <sup>a</sup> TEG®: 33.2 <sup>a</sup> 2009 - 2012	304/1	Non TEG®: 35.1 <sup>a</sup> TEG®: 37.7 <sup>a</sup>	Non TEG®: 168 (64.0%) TEG®: 29 (69.0%)	r-TEG® - patient's T Fresh whole blood Kaolin and TF added	None
Chapman 2013 [56]	Prospective	ISS 30.0 <sup>a</sup> 2010 - 2012	289/1	43.0 <sup>b</sup>	196 (68.0%)	TEG® - T not reported Citratd blood, recalcified Kaolin, stabilizers added	None
Harr 2013 [44]	Prospective	ISS 23.5 <sup>a</sup>	68/1	38.0 <sup>b</sup>	45 (66.0%)	TEG® - 37°C Citratd blood, recalcified Kaolin, stabilizers added	None
Johansson 2013 [45]	Prospective	ISS 17.0 <sup>b</sup> 2010 - 2011	182/1	43.0 <sup>b</sup>	136 (75.0%)	TEG® - 37°C Citratd blood, recalcified Kaolin and TF activated and Functional fibrinogen test	MTP (1:1:1 ratio) initially and guided by TEG® thereafter. Also TXA, CRYO and FC administered.
Lee 2013 [46]	Prospective	ISS 17.0 <sup>b</sup> 2010 - 2012	190/1	43.0 <sup>b</sup>	136 (71.6%)	TEG®, r-TEG® - T not reported Citratd blood, recalcified Kaolin and TF activated	None
Tapia 2013 [63]	Before and after study	ISS 25.0 <sup>b</sup> 2008 - 2010	289/1	35.0 <sup>b</sup>	251 (86.8%)	TEG® - 37°C Whole blood Celite activated	TEG® guided resuscitation pre MTP and guided by MTP without TEG® thereafter



**Table 1 Characteristics of the studies included in the systematic review (Continued)**

Kornblith 2014 [47]	Prospective	ISS 9.0 <sup>a</sup> Years not reported	251/1	35.0 <sup>a</sup>	202 (80.7%)	TEG <sup>®</sup> - 37°C Citratd blood, recalcified Kaolin and TF activated and functional fibrinogen test	None
Branco 2014 [48]	Prospective	ISS 1 - 51 2011	118/1	36.9 <sup>b</sup>	97 (77.1%)	TEG <sup>®</sup> - T not reported Citratd blood, recalcified Kaolin added	None

<sup>a</sup>Median, AA – arachidonic acid, ADP – adenosine diphosphate, AIS – abbreviated injury score, <sup>b</sup>Mean, CaCl<sub>2</sub> – calcium chloride, CRYO – cryoprecipitate, DVT – deep vein thrombosis, FC – fibrinogen concentrate, FFP – fresh frozen plasma, GCS – Glasgow Coma Scale, HCR – hemostatic control resuscitation, HF – hyperfibrinolysis, ISS – injury severity score, LMWH – low molecular weight heparin, MinT – minimal transfusion, ModT – moderate transfusion, MT – massive transfusion, MTP – massive transfusion protocol, Na – sodium, PCC – prothrombin complex concentrate, PE – pulmonary embolism, PLT – platelets, PM – platelet mapping, RBC – red blood cells, ROTEM<sup>®</sup> – rotational thromboelastometry, RSCT – routine screening coagulation tests, r-TEG<sup>®</sup> – rapid thromboelastography, TBI – traumatic brain injury, TEG<sup>®</sup> – thromboelastography, TF – tissue factor, TXA – tranexamic acid.

that that did not evaluate diagnostic performance against a reference standard are represented in Table 4.

### Outcomes

The included studies collectively reported on hypocoagulability, hypercoagulability, platelet dysfunction, and hyperfibrinolysis. We summarize the parameters of TEG<sup>®</sup>/ROTEM<sup>®</sup> used for diagnosis, turnaround times (TATs), and results concerning prediction, reduction, or guidance of transfusion and prediction or reduction of mortality. Details of all studies without a control group (for clinical outcomes) or a reference standard (for diagnostic performance) are given in Table 5.

### Diagnosis of early trauma coagulopathies

**Hypercoagulability** Six studies demonstrated hypercoagulability in trauma patients not detected by RSCT. Hypercoagulability was defined mostly by the manufacturer of both TEG<sup>®</sup> and ROTEM<sup>®</sup> devices, and the reference standards (where reported) were Doppler ultrasound, CT angiography, or a surgical procedure demonstrating thrombus. One study [11] demonstrated that 62% of trauma patients were hypercoagulable according to TEG<sup>®</sup> (R <3.7) on the first day after injury with normal RSCT values. Another study [19] showed higher TEG<sup>®</sup> α-angle (which reflects the degree of fibrin cross-linking) and MA (maximal amplitude) in trauma compared with RSCT (PT and aPTT) (*P* <0.05), indicating a hypercoagulable state. A study [24] detected increased *G* (shear elastic modulus strength (5,000 – MA)/(100 – MA), which reflects clot strength) in a cohort of trauma patients after splenectomy, who had more thromboembolic events, compared with patients treated nonoperatively. Another study of rapid TEG<sup>®</sup> (r-TEG<sup>®</sup>) [18] showed that increased *G* was associated with thromboembolic

complications (OR, 1.25; 95% CI, 1.12 to 1.39), after controlling for thromboprophylaxis and using the reference standards discussed earlier. When TEG<sup>®</sup> [27] was performed 24 hours after injury, trauma patients were more hypercoagulable compared with healthy volunteers across a broad range of temperatures (32°C to 38°C).

Finally, a cohort study [34] suggested an association between admission MA and pulmonary embolism (OR, 3.5 for MA >65; 95% CI, 1.69 to 7.23; and OR, 5.8 for MA >72; 95% CI, 2.85 to 11.77), after controlling for gender, race, age, and ISS.

**Hyperfibrinolysis (HF)** Only one study [14] compared HF detected with ROTEM<sup>®</sup> with a laboratory gold standard and showed that ROTEM<sup>®</sup> had satisfactory diagnostic properties for HF, defined by laboratory measurement of euglobin lysis time (ELT). However, the sample size was very small (*n* = 23, of which five had HF), limiting the strength of inferences.

**Platelet dysfunction** With TEG<sup>®</sup> platelet-mapping (PM) test, a study [13] showed that patients with TBI had more platelet dysfunction on admission, measured by lower platelet response to arachidonic acid (AA) but not to adenosine diphosphate (ADP), compared with non-TBI trauma patients, alcohol abusers, and healthy volunteers (*P* <0.001). Another study [41], using the same technique, found lower platelet response to both AA and ADP in trauma patients versus healthy volunteers (*P* <0.0001). With ROTEM<sup>®</sup>, one study [42], comparing healthy volunteers with trauma patients, speculated that an observed difference in clot strength arose from platelet dysfunction. A related study [65] of ROTEM<sup>®</sup> at emergency department (ED) admission demonstrated significantly lower values of platelet component of clot elasticity (MCE EXTEM, ROTEM<sup>®</sup> extrinsically

**Table 2 Newcastle-Ottawa score [6] for the cohort studies included in the systematic review**

Reference	Representativeness of the exposed cohort	Selection of non-exposed cohort	Ascertainment of exposure	Outcome not present at start	Comparability of controls	Assessment of outcome	Adequate follow-up duration	Loss to follow-up	Total score
Kaufmann 1997 [9]	*	-	*	*	-	*	*	*	6/9
Watts 1998 [10]	*	-	*	*	-	*	*	*	6/9
Schreiber 2005 [11]	*	-	*	*	-	*	*	*	6/9
Rugeri 2007 [12]	*	-	*	*	-	*	*	*	6/9
Nekdulov 2007 [13]	*	-	*	*	-	*	*	*	6/9
Levrat 2008 [14]	*	-	*	*	-	*	*	*	6/9
Park 2008 [57]	*	-	*	*	-	*	*	*	6/9
Plotkin 2008 [15]	*	-	*	*	-	*	*	*	6/9
Carroll 2009 [16]	*	-	*	*	-	*	*	*	6/9
Jeger 2009 [17]	*	-	*	*	-	*	*	*	6/9
Kashuk 2009 [49]	*	-	*	*	-	*	*	*	6/9
Kashuk 2009 [18]	*	-	*	*	-	*	*	*	6/9
Park 2009 [19]	*	-	*	*	-	*	*	*	6/9
Schöchgl 2009 [58]	*	-	*	*	-	*	*	*	6/9
Doran 2010 [20]	*	-	*	*	-	*	*	-	5/9
Kashuk 2010 [21]	*	-	*	*	-	*	*	*	6/9
Leemann 2010 [22]	*	-	*	*	-	*	*	*	6/9
Schochl 2010 [59]	*	-	*	*	-	*	*	*	6/9
Schochl 2011 [23]	*	-	*	*	-	*	*	*	6/9
Watters 2010 [24]	*	-	*	*	-	*	*	*	6/9
Cotton 2011 [25]	*	-	*	*	-	*	*	*	6/9
Davenport 2011 [26]	*	-	*	*	-	*	*	*	6/9
Davenport 2011 [50]	*	-	*	*	-	*	*	-	5/9
Differding 2011 [27]	*	-	*	*	-	*	*	*	6/9
Jansen 2011 [28]	*	-	*	*	-	*	*	*	6/9
Nystrup 2011 [29]	*	-	*	*	-	*	*	*	6/9

**Table 2 Newcastle-Ottawa score [6] for the cohort studies included in the systematic review (Continued)**

Ostrowski 2011 [30]	*	-	*	*	-	*	*	*	6/9
Schöchl 2011 [51]	*	*	*	*	*	*	*	*	8/9
Schöchl 2011 [31]	*	-	*	*	-	*	*	*	6/9
Tauber 2011 [32]	*	-	*	*	-	*	*	*	6/9
Theusinger 2011 [60]	*	-	*	*	-	*	*	*	6/9
Cotton 2012 [33]	*	-	*	*	-	*	*	*	6/9
Cotton 2012 [34]	*	-	*	*	-	*	*	*	6/9
Davis 2013 [61]	*	-	*	*	-	*	*	*	6/9
Holcomb 2012 [35]	*	-	*	*	-	*	*	*	6/9
Ives 2012 [36]	*	-	*	*	-	*	*	*	6/9
Jeger 2012 [52]	*	-	*	*	-	*	*	*	6/9
Kashuk 2012 [37]	*	*	*	*	*	*	*	*	8/9
Kunio 2012 [62]	*	-	*	*	-	*	*	*	6/9
Kutcher 2012 [38]	*	-	*	*	-	*	*	*	6/9
Nascimento 2012 [39]	*	-	*	*	-	*	*	*	6/9
Ostrowski 2012 [53]	*	-	*	*	-	*	*	*	6/9
Pezold 2012 [54]	*	-	*	*	-	*	*	*	6/9
Raza 2013 [55]	*	-	*	*	-	*	*	*	6/9
Rourke 2012 [40]	*	-	*	*	-	*	*	*	6/9
Wohlauer 2012 [41]	*	-	*	*	-	*	*	*	6/9
Woolley 2013 [42]	*	-	*	*	-	*	*	*	6/9
Chapman 2013 [43]	*	-	*	*	-	*	*	*	6/9
Chapman 2013 [56]	*	-	*	*	-	*	*	*	6/9
Harr 2013 [44]	*	-	*	*	-	*	*	*	6/9
Johansson 2013 [45]	*	-	*	*	-	*	*	*	6/9
Lee 2013 [46]	*	-	*	*	-	*	*	*	6/9

**Table 2 Newcastle-Ottawa score [6] for the cohort studies included in the systematic review (Continued)**

Tapia 2013 [63]	*	*	*	*	*	*	*	*	8/9
Kornblith 2014 [47]	*	-	*	*	-	*	*	*	6/9
Branco 2014 [48]	*	-	*	*	-	*	*	*	6/9

Refer to reference [7] for a description of Newcastle-Ottawa Quality Assessment Scale for cohort studies. In general, more stars denote higher quality. "Representativeness" is awarded a star if the cohort is truly or somewhat representative of the population of interest. For selection of the nonexposed cohort, a star is awarded if it is drawn from the same population as the exposed cohort. The relevant exposure in this review is management by using TEG<sup>®</sup>/ROTEM<sup>®</sup>; we considered a non-exposed cohort to be one that was managed without TEG<sup>®</sup>/ROTEM<sup>®</sup>; several other studies [12,13,19,24,27,32,41,42,44,60,61] used healthy or other hospitalized controls to examine associations between TEG<sup>®</sup>/ROTEM<sup>®</sup> abnormalities and outcomes. Exposure is satisfactorily ascertained if data are collected from a secure record. A star is awarded if the outcome is not present at the start of the study. A maximum of two stars can be given for "Comparability of controls" for controlling of confounders in either the design (matching) or analysis (statistical adjustment) phase. We also gave one star when selection criteria appeared to create comparable groups via restriction. "Assessment of outcome" is awarded a star if the outcomes were assessed by independent blind assessment or record linkage; we also considered the outcome of mortality to be adequately assessed in all studies reporting it was due to low risk of bias. The duration of follow-up was considered adequate if it was long enough for the outcomes to occur. Completeness of follow-up was considered adequate if all patients were accounted for or if the number lost to follow-up was sufficiently low to be unlikely to introduce bias.

activated test with TF and MCE FIBTEM, ROTEM<sup>®</sup> fibrin-based extrinsically activated test with TF and the platelet inhibitor cytochalasin D) in trauma nonsurvivors vs. survivors ( $P = 0.0012$ ).

**Hypocoagulability** Six studies directly compared TEG<sup>®</sup> or ROTEM<sup>®</sup> with RSCT, with variable results for diagnostic performance. One study [9] demonstrated that TEG<sup>®</sup> detected hypocoagulability in 45 (85.5%) of 52 patients, whereas only one (1.9%) of 52 was hypocoagulable by elevated PT/aPTT and two (3.8%) of 52 were hypercoagulable by elevated platelet count. In a cohort [12] of trauma patients and healthy volunteers, EXTEM A15  $\geq$  32 mm (amplitude at 15 minutes) and FIBTEM A10  $\geq$  5 mm were sensitive (87% and 91%) and specific (100% and 85%) for detection of PT >1.5 of control value and fibrinogen <1 g/L, respectively. Doran [20] found that 16 (64%) of 25 patients were hypocoagulable by ROTEM<sup>®</sup> trace, and only 10% had abnormal RSCT ( $P = 0.0005$ ). In contrast, another study [39] ( $n = 219$ ) found that TEG<sup>®</sup>-R (R, reaction time, defined as the time until a clot firmness of 2 mm is achieved, corresponding to CT, clotting time, in ROTEM<sup>®</sup>) performed worse than INR for the diagnosis of vitamin K deficiency in trauma patients (clotting factor activity used as gold standard). TEG<sup>®</sup>-R (compared with INR >1.5) had a sensitivity of 33% (67% for INR), specificity of 95% (98% for INR), positive predictive value (PPV) of 47% (84% for INR), and negative predictive value (NPV) of 92% (96% for INR). In another cohort [26] ( $n = 300$ ), ROTEM<sup>®</sup> parameters of CFT (clot-formation time),  $\alpha$ -angle, A5 (clot amplitude 5 minutes after CT) and MCF (maximum clot firmness) were significantly different in the group with coagulopathy, defined by INR >1.2. A5  $\leq$  35 mm had a sensitivity of 77% and specificity of 87% for the detection of coagulopathy. Finally, a recent large study [40] ( $n = 517$ ) found that ROTEM<sup>®</sup> EXTEM, and FIBTEM measures of A5 and MCF were significantly correlated with fibrinogen levels (EXTEM A5,  $r^2 = 0.35$ , and MCF,  $r^2 = 0.26$ ; FIBTEM

A5,  $r^2 = 0.44$ , and MCF,  $r^2 = 0.27$ ; all  $P < 0.001$ ). The sensitivity/specificity of EXTEM A5 < 36 mm (FIBTEM A5 < 9.5 mm) for discriminating patients with admission fibrinogen <1.5 g/L were 53%/87% (78%/70%; ROC AUC 0.8, 95% CI 0.7 to 0.9 for both).

One study [46] comparing the same parameters measured by r-TEG<sup>®</sup> and conventional kaolin-activated TEG<sup>®</sup> found strong correlation for MA (marker of platelet function;  $r = 0.80$ ); moderate correlation for G (overall clot strength;  $r = 0.70$ ), k (speed of clot formation;  $r = 0.66$ ), and  $\alpha$ -angle (degree of fibrin cross-linking;  $r = 0.38$ ); and poor correlation for LY30 (degree of fibrinolysis;  $r = 0.19$ ).

Although TEG<sup>®</sup> and r-TEG<sup>®</sup> may be moderately sensitive in detecting abnormal clot strength, they have not differentiated between fibrinogen and platelet contributions to clot integrity. Recent studies of the TEG<sup>®</sup>-based functional fibrinogen assay (FF) have examined the relative contribution each. By using Kaolin TEG<sup>®</sup> MA to define coagulopathy, Johansson [45] showed that TEG<sup>®</sup>-FF MA and G were lower in hypocoagulable patients and significantly higher in hypercoagulable patients compared with patients with normal Kaolin TEG<sup>®</sup> MA ( $P < 0.001$ ). In another study [47], coagulopathic patients (INR  $\geq$  1.3) had lower admission fibrinogen contribution to MA than did noncoagulopathic patients (24.7% versus 31.2%;  $P < 0.05$ ). Platelet contribution to MA was higher than fibrinogen at all time points, decreased over time, and stabilized at 72 hours (69.4% at 0 hours, 56.2% at 72 hours). In contrast, fibrinogen contribution to MA increased over time and stabilized at 72 hours (30.6% at 0 hours, 43.8% at 72 hours).

#### Turnaround times

Four studies reported on the use of TEG<sup>®</sup> and ROTEM<sup>®</sup> as POC devices. Carroll [16] demonstrated no statistical difference in the diagnosis of acute trauma coagulopathies when collecting blood on site or 1 hour after admission in the emergency department (ED), except for a small but statistically significant change in MA (60.6 (SD 11.1) mm

**Table 3 Assessment of studies of diagnostic performance of TEG®/ROTEM® by using the QUADAS-2 [8] tool**

Reference	Risk of bias				Applicability concerns		
	Patient selection	Index test	Reference standard	Flow and timing	Patient selection	Index test	Reference standard
Kaufmann 1997 [9]	?	↑	↑	↓	↓	↓	↓
Watts 1998 [10]	↓	?	↓	↓	↓	↓	↓
Schreiber 2005 [11]	↑	?	?	↓	↓	↓	↓
Rugeri 2007 [12]	↑	↓	↓	↓	↑	↓	↓
Nekludov 2007 [13]	↑	?	?	↓	↑	↓	↓
Levrat 2008 [14]	↓	?	↑	↓	↓	↓	↑
Park 2008 [57]	↑	?	?	↓	↓	↓	↓
Plotkin 2008 [15]	↑	?	?	↑	↑	↓	↓
Carroll 2009 [16]	↓	?	?	↓	↓	↓	↓
Jeger 2009 [17]	↑	?	?	↓	↓	↓	↓
Kashuk 2009 [49]	↑	?	↑	↓	↑	↓	↓
Kashuk 2009 [18]	↑	?	?	↓	↓	↓	↓
Park 2009 [19]	↑	?	?	↓	↑	↓	↓
Schöchgl 2009 [58]	↓	?	?	↓	↓	↓	↓
Doran 2010 [20]	↑	?	?	↓	↑	↓	↓
Kashuk 2010 [21]	↓	?	?	↓	↓	↓	↓
Leemann 2010 [22]	↓	?	?	↓	↓	↓	↓
Schochl 2010 [59]	↑	↓	↓	↓	↓	↓	↓
Schochl 2011 [23]	↓	?	?	↓	↓	↓	↓
Watters 2010 [24]	↓	?	?	↓	↓	↓	↓
Cotton 2011 [25]	↓	?	?	↓	↓	↓	↓
Davenport 2011 [26]	↓	?	?	↓	↓	↓	↓
Davenport 2011 [50]	↓	?	?	↓	↓	↓	↓
Nystrup 2011 [29]	↑	?	?	↓	↓	↓	↓
Ostrowski 2011 [30]	↓	?	?	↓	↓	↓	↓
Schöchgl 2011 [31]	↓	?	?	↓	↓	↓	↓
Tauber 2011 [32]	↓	↓	↓	↓	↓	↓	↓
Theusinger 2011 [60]	↑	?	?	↓	↑	↓	↓
Cotton 2012 [33]	↓	?	?	↓	↓	↓	↓
Cotton 2012 [34]	↓	?	?	↓	↓	↓	↓
Davis 2013 [61]	↑	?	?	↓	↑	↓	↓
Holcomb 2012 [35]	↓	?	?	↓	↓	↓	↓
Ives 2012 [36]	↑	?	?	↓	↓	↓	↓
Jeger 2012 [52]	↓	?	↓	↓	↓	↓	↓
Kashuk 2012 [37]	↓	↓	↓	↓	↓	↓	↓
Kunio 2012 [62]	?	?	?	↓	↓	↓	↓
Kutcher 2012 [38]	↓	?	?	↓	↓	↓	↓
Nascimento 2012 [39]	↓	↓	↓	↓	↓	↓	↓
Ostrowski 2012 [53]	↑	?	?	↓	↓	↓	↓
Pezold 2012 [54]	↓	?	?	↓	↓	↓	↓
Raza 2013 [55]	↓	?	?	↓	↓	↓	↓
Rourke 2012 [40]	↓	?	?	↓	↓	↓	↓

**Table 3 Assessment of studies of diagnostic performance of TEG®/ROTEM® by using the QUADAS-2 [8] tool (Continued)**

Woolley 2013 [42]	↑	?	?	↓	↑	↓	↓
Harr 2013 [44]	?	?	?	↓	↓	↓	↓
Johansson 2013 [45]	↓	?	?	↓	↓	↓	↓
Kornblith 2014 [47]	?	?	?	↓	↓	↓	↓
Branco 2014 [48]	↑	?	?	↓	↓	↓	↓

We assessed studies using QUADAS-2 [8] if they evaluated diagnostic performance of TEG®/ROTEM® compared with standard laboratory tests. ↑ denotes high risk of bias, ↓ denotes low risk of bias, and ? denotes unclear risk of bias.

on site and 63.4 (SD 12.1) mm in ED;  $P = 0.014$ ). A cohort study [17] demonstrated that r-TEG® had a shorter TAT (time to MA) by a median (IQR) of 10.8 (1.1 to 18.5) minutes compared with TEG®. In another cohort [26], laboratory PT had a median TAT of 78 minutes (IQR, 62 to 103 minutes), whereas ROTEM® A5 was available by 5 minutes.

Finally, in another study [25], early r-TEG® values (ACT [activated clotting time],  $k$ -time, and  $r$ -value) were available within 5 minutes, late r-TEG® values (MA and  $\alpha$ -angle) within 15 minutes, and RSCTs within 48 minutes ( $P < 0.001$  for all comparisons with r-TEG®).

#### Blood transfusion

**Prediction of massive transfusion (MT) and any transfusion** Several studies compared ROTEM® and TEG® parameters with RSCTs for prediction of MT (defined by most studies as transfusion of  $\geq 10$  RBC units within 24 hours of trauma). Davenport [26] found better sensitivity (71% versus 42%) for ROTEM® A5  $\leq 35$  mm versus INR  $> 1.2$ , but worse specificity (85% versus 94%). Another study [31] found that FIBTEM (0 to 3 mm) had the highest AUC (0.84; 95% CI, 0.79 to 0.88) among ROTEM® tests for prediction of MT, but hemoglobin

(AUC 0.87; 95% CI, 0.83 to 0.91) and PT (AUC, 0.87; 95% CI, 0.83 to 0.90) were better predictors.

A third study [22] showed multiple ROTEM® tests to be associated with MT; in a multivariable analysis limited by few events, hemoglobin  $\leq 100$  g/L (OR, 18.18; 95% CI, 2.73 to 125.00) was a stronger predictor of MT than abnormal MCF (OR, 8.47; 95% CI, 1.19 to 62.50). Similarly, RCSTs and TEG® had similar abilities to predict MT (G AUC 0.89; 95% CI, 0.89 to 0.96; INR AUC, 0.92; 95% CI, 0.86 to 0.98; PTT AUC 0.90; 95% CI, 0.83 to 0.97) [54].

ROTEM® parameters significantly associated with MT include increased CFT [22,31], decreased MCF [22,31], prolonged EXTEM and INTEM CT (intrinsically activated test using ellagic acid, clotting time) [31] and FIBTEM A10 (ROC AUC, 0.83; 95% CI, 0.78 to 0.87) [31]. For TEG®, statistically significant differences in  $\alpha$  angle, MA, K, G (at 1 hour), and estimated lysis according to transfusion need (minimal, moderate, or massive) were reported [21]. Another study [36] found that patients with HF, defined by estimated lysis  $> 15\%$ , had a greater need for MT (76.9% versus 8.7%; adjusted OR, 19.1; 95% CI, 3.6 to 101.3).

Finally, a recent study demonstrated that a TEG® LY30 (percentage decrease in clot amplitude at 30 minutes

**Table 4 Details of TEG®/ROTEM® for studies that did not evaluate diagnostic performance against a reference standard**

Reference	Performed in a timely manner	All results reported	Technique described in detail	Independently interpreted from routine screening coagulation tests
Differding 2011 [27]	Yes	Yes	Yes	Yes
Jansen 2013 [28]	Yes	Yes	No	Yes
Schöchel 2011 [51]	Yes	Yes	No	Yes
Wohlauer 2012 [41]	Yes	Yes	Yes	Yes
Chapman 2013 [43]	Yes	Yes	Yes	Yes
Chapman 2013 [56]	Yes	No	No	Yes
Lee 2013 [46]	Yes	Yes	No	Yes
Tapia 2013 [63]	Yes	Yes	Yes	Yes

**Table 5 Main findings of the included studies**

Reference	1. Findings on diagnosis	2. Findings on transfusion	3. Findings on mortality
Kaufmann 1997 [9]	1. Of 69 patients, 45 were hypercoagulable (mean ISS 13.1) and seven were hypocoagulable (mean ISS, 28.6) by TEG®. Only one was hypocoagulable by elevated PT/aPTT, and two were hypercoagulable by elevated PLT		
	2. Only ISS ( $P < 0.001$ ) and TEG® ( $P < 0.05$ ) predicted transfusion within the first 24 h after injury. Six of the seven hypocoagulable patients received blood within the first 24 hours		
	3. None		
Watts 1998 [10]	1. Hypothermic patients (34°C) presented significantly lower TEG® $\alpha$ -angle, K and MA values ( $P < 0.001$ ) even though platelet count, PT, and aPTT were within normal range, and correlated with fluid and blood transfusion.		
	2. None		
	3. None		
Schreiber 2005 [11]	1. INR and aPTT failed to detect early hypercoagulability, showing that TEG® is more sensitive. Women are more hypercoagulable than men within the first 24 hours.		
	2. None		
	3. None		
Rugeri 2007 [12]	1. Significant correlation between PT - A15-EXTEM, between aPTT - CFT-INTEM, between fibrinogen - A10-FIBTEM and between PLT - A15-INTEM. A cut off value of A15-EXTEM at 32 mm and A10-FIBTEM at 5 mm presented a good sensitivity (87 and 91%) and specificity (100 and 85%) to detect PT >1.5 and a fibrinogen less than 1 g/L, respectively.		
	2. None		
	3. None		
Nekdulov 2007 [13]	1. TBI patients had a lower PLT count ( $180 \pm 68 \times 10^9$ ; mean $\pm$ SD) and longer bleeding time ( $674 \pm 230$ sec) than healthy controls ( $256 \pm 43 \times 10^9$ , $p < .01$ ) and ( $320 \pm 95$ sec, $p < .005$ ) respectively. TEG®-PM showed reduced PLT response to AA and ADP (0-86%, mean 22%) compared to healthy controls (57-89%, mean 73%).		
	2. None		
	3. None		
Levrat 2008 [14]	1. MCF showed the best correlation with the ELT when compared with amplitude and CLI. HF patients also had greater ROTEM® abnormalities, lower INR, lower fibrinogen levels and were more severely injured ( $\uparrow$ ISS) than the control group (all $p < .05$ ).		
	2. None		
	3. Patients with hyperfibrinolysis had higher mortality rate (100%, CI: 48-100% vs. 11% CI: 5-20%)		
Park 2008 [57]	1. None		
	2. None		
	3. Multiple logistic regression analysis identified MA as an independent risk factor for death, AUC ROC 0.961 (95% CI, 0.891, 1.000)		
Plotkin 2008 [15]	1. Increased K time, reduced $\alpha$ -angle and decreased MA demonstrated hypocoagulation.		
	2. INR, PT and aPTT did not correlate with the use of blood products ( $r = .57$ , $p < .01$ ). MA correlated with blood product use as well as PLT count. Patients with reduced MA used more blood products and had reduced PLT counts and hematocrit.		
	3. None		
Carroll 2009 [16]	1. TEG® parameters did not change significantly from the ED sampled to OR samples.		
	2. Abnormal MA-ADP at 30 min correlated with the need for transfusion ( $p = .004$ ).		
	3. R and MA correlated importantly with fatality (both $p < .001$ ). HF was an independent predictor of fatality ( $p = .001$ by chi square testing).		
Jeger 2009 [17]	1. Strong correlations between the values of K, $\alpha$ angle and MA ( $p < 0.01$ ). Moderate correlation between K and both INR and PLT count and between MA and both INR and PLT count ( $p < 0.05$ ). There was decrease in the time for TEG® results with r-TEG®.		
	2. None		
	3. None		
Kashuk 2009 [49]	1. None		
	2. Lab tests triggers result in blood product administration in 73.1% compared with 53.9% based on r-TEG® thresholds ( $p = .03$ ). FFP administration guided by INR triggers would have been higher (61.5% by INR triggers versus 26.9% by r-TEG®-ACT triggers, $p = .003$ ).		
	3. None		

**Table 5 Main findings of the included studies (Continued)**

Kashuk 2009 [18]	<ol style="list-style-type: none"><li>1. 67% of patients were hypercoagulable by r-TEG<sup>®</sup>. 19% of the hypercoagulable group suffered a TE, and 12% had TE predicted by prior r-TEG<sup>®</sup>. No patients with normal coagulability by r-TEG<sup>®</sup> had an event (<math>p &lt; .001</math>). G value was the strongest predictor of TE after controlling for thromboprophylaxis (OR: 1.25, 95% CI: 1.12-1.39). For every 1 dyne/cm<sup>2</sup> increase in G, the <i>odds ratio</i> of a TE increased by 25%.</li><li>2. None</li><li>3. None</li></ol>
Park 2009 [19]	<ol style="list-style-type: none"><li>1. PT and aPTT were prolonged compared with controls (<math>p &lt; .05</math>). All other parameters showed hypercoagulability (low protein C, high fibrinogen level and low TAT levels). MA and <math>\alpha</math>-angle were also higher compared with controls (<math>p &lt; .05</math>). PT and aPTT in this population were increased and did not detect hypercoagulability, which was demonstrated by TEG<sup>®</sup>.</li><li>2. None</li><li>3. None.</li></ol>
Schöchl 2009 [58]	<ol style="list-style-type: none"><li>1. None</li><li>2. None.</li><li>3. Prolonged CFT and lower PLT contribution to MCF were associated with increased mortality (<math>p = .042</math> and <math>p = .026</math> respectively). The observed mortality was higher than the expected mortality as per TRISS (88 vs. 70%, <math>p = .039</math>).</li></ol>
Doran 2010 [20]	<ol style="list-style-type: none"><li>1. MCF was abnormal in all MTP cases. A10 is subsequently associated with an abnormal MCF. 64% of all patients were coagulopathic by TEM trace and only 10% had abnormal lab tests (<math>p = .0005</math>).</li><li>2. None</li><li>3. None</li></ol>
Kashuk 2010 [21]	<ol style="list-style-type: none"><li>1. 34% of injured patients requiring MT had PF (ANOVA, <math>p &lt; .0001</math>). PF occurred early (median 58 minutes). Every 1 unit drop in G increased the risk of PF by 30%</li><li>2. None</li><li>3. The risk of death correlated significantly with PF (<math>p = .026</math>) and every 1 unit drop in G increased risk of death by 10%.</li></ol>
Leemann 2010 [22]	<ol style="list-style-type: none"><li>1. MT patients had significantly altered ROTEM<sup>®</sup> values on admission compared with non-MT patients. An increase in the CFT (<math>p = .001</math>), a shortening of the MCF (<math>p &lt; .001</math>), and a shortening of the amplitude at all time-points (10/20/30 minutes) were observed in MT patients.</li><li>2. Variables independently associated with MT included a hemoglobin level <math>&lt; 10</math> g/dL and an abnormal MCF value (AUC ROC 0.831 [95% CI: 0.719–0.942]).</li><li>3. None</li></ol>
Schochl 2010 [59]	<ol style="list-style-type: none"><li>1. None</li><li>2. None</li><li>3. The difference in mortality, after excluded patients with TBI, was 14% observed versus 27.8% predicted by TRISS and 24.3% predicted by RISC. The study shows a favorable survival rate.</li></ol>
Schochl 2011 [23]	<ol style="list-style-type: none"><li>1. ROTEM<sup>®</sup> analysis revealed shorter clotting times in EXTEM and INTEM (<math>p &lt; .001</math>), shorter CFT in EXTEM and INTEM (<math>p &lt; .0001</math>), and higher MCF in EXTEM, INTEM, and FIBTEM (<math>p &lt; .01</math>) in survivors compared with non-survivors, in severe isolated TBI.</li><li>2. According to the degree of coagulopathy, non-survivors received more RBC (<math>p = .016</math>), fibrinogen concentrate (<math>p = .01</math>), and PCC (<math>p &lt; .001</math>) within 24 h of arrival in the ED.</li><li>3. Logistic regression analysis revealed EXTEM with cytochalasin D (FIBTEM) MCF and aPTT to have the best predictive value for mortality.</li></ol>
Watters 2010 [24]	<ol style="list-style-type: none"><li>1. Cloth strength baseline and at follow up were elevated in the splenectomy group and not in the control group (<math>p &lt; .01</math>). Platelet count, fibrinogen, aPTT were also elevated in the splenectomy group. In this population TEG<sup>®</sup> and RSCT were able to diagnose hypercoagulability together.</li><li>2. None</li><li>3. None</li></ol>
Cotton 2011 [25]	<ol style="list-style-type: none"><li>1. Early r-TEG<sup>®</sup> values (ACT, <math>k</math>-time, and <math>r</math>-value) were available within 5 min. Late r-TEG<sup>®</sup> values (MA and <math>\alpha</math>-angle) within 15 min, and RSCTs within 48 min (<math>p &lt; .001</math>). ACT, <math>r</math>-value, and <math>k</math>-time showed strong correlation with PT, INR and aPTT whereas <math>\alpha</math>-angle correlated with platelet count (both <math>p &lt; .001</math>).</li><li>2. Linear regression demonstrated that ACT predicted RBC, plasma and PLT transfusions within the first 2 h of arrival. Controlling for all demographics and ED vitals, ACT <math>&gt; 128</math> predicted MT in the first 6 h. In addition, ACT <math>&lt; 105</math> predicted patients who did not receive any transfusions in the first 24 h.</li><li>3. None</li></ol>



**Table 5 Main findings of the included studies (Continued)**

Davenport 2011 [26]	<ol style="list-style-type: none"><li>1. CFT, <math>\alpha</math>, A5 and MCF are significantly different in the group with coagulopathy. A5 <math>\leq</math> 35 mm detects great percentage of patients with coagulopathy with lower false positive rates than PT (detected 77% of ATC, with 13% false positive).</li><li>2. Patients with A5 <math>\leq</math> 35 mm were more likely to receive RBC (46% vs. 17%, <math>p &lt; .001</math>) and FFP (37% vs. 11%, <math>p &lt; .001</math>) transfusions. A5 identified patients who would require MT (rate of 71% vs. 43% for INR <math>&gt;</math> 1.2, <math>p &lt; .001</math>).</li><li>3. None</li></ol>
Davenport 2011 [50]	<ol style="list-style-type: none"><li>1. None</li><li>2. Coagulation profile deteriorated with low FFP:PRBC ratios <math>&lt;</math> 1:2. Maximal hemostatic effect was observed in the 1:2 to 3:4 groups: 12% decrease in PT (<math>p = .006</math>), 56% decrease CT (<math>p = .047</math>), and 38% increase in MCF (<math>p = .024</math>). Transfusion with <math>\geq</math> 1:1 ratio did not confer any additional improvement. There was a marked variability in response to FFP, and hemostatic function deteriorated in some patients exposed to 1:1 ratios. The beneficial effects of plasma were confined to patients with coagulopathy.</li><li>3. None</li></ol>
Differding 2011 [27]	<ol style="list-style-type: none"><li>1. R increased (<math>p &lt; .001</math>) and <math>\alpha</math>-angle decreased (<math>p &lt; .01</math>) in both groups (patients and controls) as T°C decreased. Between groups, R, <math>\alpha</math>-angle, and MA were significantly different at each T°C (<math>p &lt; .01</math>), with patients being more hypercoagulable. R and <math>\alpha</math>-angle were more affected by T°C in controls compared with patients (<math>p &lt; .02</math>). Temperature did not alter coagulability in the range studied in trauma patients while in the controls it did change.</li><li>2. None</li><li>3. None</li></ol>
Jansen 2013 [28]	<ol style="list-style-type: none"><li>1. Repeated ROTEM® tests on samples stored at 37°C for a median of 51 minutes, show improved MCF (22 mm vs. 54 mm, <math>p &lt; .001</math>) and <math>\alpha</math>-angle (30.5 vs. 59.5°, <math>p = .004</math>) when compared to analysis at the moment of venipuncture.</li><li>2. None</li><li>3. None.</li></ol>
Nystrup 2011 [29]	<ol style="list-style-type: none"><li>1. Patients with a reduced MA (<math>&lt;</math> 50 mm) evaluated by TEG®, presented with a higher ISS - 27 (95% CI, 20–34) vs. 19 (95% CI, 17–22), than the rest of the cohort.</li><li>2. MA correlated with the amount of RBC (<math>p = .01</math>), FFP (<math>p = .04</math>) and PLT (<math>p = .03</math>) transfused during the first 24 h of admission.</li><li>3. Patients with <math>\downarrow</math> MA demonstrated <math>\uparrow</math> 30-day mortality (47% vs. 10%, <math>p &lt; .001</math>). By logistic regression <math>\downarrow</math>MA was an independent predictor of <math>\uparrow</math> mortality after adjusting for age and ISS.</li></ol>
Ostrowski 2011 [30]	<ol style="list-style-type: none"><li>1. Fibrinogen and PLT count were associated independently with clot strength in patients with ISS <math>\leq</math> 26 whereas only fibrinogen was associated independently with clot strength in patients with ISS <math>&gt;</math> 26. In patients with ISS <math>&gt;</math> 26, adrenaline and sCD40L were independently negatively associated with clot strength.</li><li>2. None</li><li>3. None</li></ol>
Schöchl 2011 [51]	<ol style="list-style-type: none"><li>1. None</li><li>2. RBC transfusion was avoided in 29% of patients in the fibrinogen-PCC group compared with only 3% in the FFP group (<math>p &lt; .001</math>). Transfusion of PLT was avoided in 91% of patients in the fibrinogen-PCC group, compared with 56% in the FFP group (<math>p &lt; .001</math>).</li><li>3. Mortality was comparable between groups: 7.5% in the fibrinogen-PCC group and 10.0% in the FFP group (<math>p = .69</math>).</li></ol>
Schöchl 2011 [31]	<ol style="list-style-type: none"><li>1. EXTEM and INTEM CT and CFT were significantly prolonged and MCF was significantly lower in the MT group versus the non-MT group (<math>p &lt; .0001</math> for all comparisons).</li><li>2. Of patients admitted with FIBTEM MCF 0 to 3 mm, 85% received MT. The best predictive values for MT were provided by hemoglobin and Quick value (AUC ROC: 0.87 for both parameters). Similarly high predictive values were observed for FIBTEM MCF (0.84) and FIBTEM A10 (0.83).</li><li>3. None</li></ol>
Tauber 2011 [32]	<ol style="list-style-type: none"><li>1. In patients with or without TBI, the prevalence of low fibrinogen, impaired fibrin polymerization and reduced MCF was 26%, 30%, and 22%, respectively, and thus higher than the prolonged INR (14%). All patients showed <math>\uparrow</math> F1 + 2 and TAT and low AT levels, indicating <math>\uparrow</math> thrombin formation.</li><li>2. MCF FIBTEM correlated with RBC transfusion (OR 0.92, 95% CI 0.87–0.98).</li><li>3. ROTEM® parameters correlated with RSCTs and with mortality (FIBTEM and EXTEM MCF (<math>p = .006</math> and <math>p = .001</math> respectively). EXTEM MCF was independently associated with early mortality. HF <math>\uparrow</math> fatality rates and occurred as frequently in isolated TBI as in polytrauma.</li></ol>

**Table 5 Main findings of the included studies (Continued)**

Theusinger 2011 [60]	<ol style="list-style-type: none"> <li>1. None</li> <li>2. None</li> <li>3. Mortality in the trauma HF group (77% ± 12%) as diagnosed by ROTEM® was significantly higher than in the nontrauma HF group (41% ± 10%, 95% CI 5%–67%) and the matched trauma group (33% ± 10%, 95% CI 13%–74%). HF is significantly (<math>p = .017</math>) associated with mortality in trauma patients.</li> </ol>
Cotton 2012 [33]	<ol style="list-style-type: none"> <li>1. Controlling for ISS and BD on arrival, pre-hospital fluid was associated with a significant ↑ in likelihood of HF. Each additional liter of crystalloid was associated with a 15% ↑ OR of HF. The <i>in vitro</i> model found that hemodilution to 15% of baseline and TF + t-PA was required to achieve an LY30 of 50%.</li> <li>2. None</li> <li>3. Compared with patients without HF, the HF group had higher mortality (76% vs. 10%); all <math>p &lt; .001</math>.</li> </ol>
Cotton 2012 [34]	<ol style="list-style-type: none"> <li>1. The PE group had admission higher MA (66 vs. 63, <math>p = .05</math>) and higher ISS (median, 31 vs. 19, <math>p = .002</math>). When controlling for gender, race, age, and ISS, elevated MA at admission was an independent predictor of PE with an OR of 3.5 for MA &gt; 65 and 5.8 for MA &gt; 72.</li> <li>2. None</li> <li>3. None</li> </ol>
Davis 2013 [61]	<ol style="list-style-type: none"> <li>1. None</li> <li>2. None</li> <li>3. Median ADP inhibition of platelet function, as measured by TEG® platelet-mapping analysis, was significantly greater in TBI non-survivors (91.7%) compared to survivors (48.2%) (<math>p = .035</math>).</li> </ol>
Holcomb 2012 [35]	<ol style="list-style-type: none"> <li>1. Overall, r-TEG® correlated with RSCTs, and could replace RSCTs on admission.</li> <li>2. ACT-predicted RBC transfusion, and the <math>\alpha</math>-angle predicted massive RBC transfusion better than PT, aPTT or INR (<math>p &lt; .001</math>). The <math>\alpha</math>-angle was superior to fibrinogen for predicting FFP transfusion (<math>p &lt; .001</math>); MA was superior to PLT count for predicting PLT transfusion (<math>p &lt; .001</math>); and LY-30 documented fibrinolysis. These correlations improved for transfused, shocked or TBI patients.</li> <li>3. None</li> </ol>
Ives 2012 [36]	<ol style="list-style-type: none"> <li>1. By the 6-h sampling, 8 (61.5%) of the HF patients (detected by TEG® parameters) had died from hemorrhage. Survivors at this point demonstrated correction of coagulopathy.</li> <li>2. Compared with patients without HF, patients with HF had a greater need for MT (76.9% vs. 8.7%; adjusted OR = 19.1; 95% CI, 3.6 - 101.3)</li> <li>3. On LR, HF was a strong predictor of early mortality (OR = 25.0; 95% CI, 2.8- 221.4), predicting 53% of early deaths. Patients with HF had ↑ early mortality (69.2% vs. 1.9%; adjusted OR = 55.8; 95% CI, 7.2-432.3) and in-hospital mortality (92.3% vs. 9.5%; adjusted OR = 55.5; 95% CI, 4.8 - 649.7).</li> </ol>
Jeger 2012 [52]	<ol style="list-style-type: none"> <li>1. None</li> <li>2. RSCTs correlate moderately with r-TEG® parameters (<math>R: 0.44</math>–<math>0.61</math>). Kaolin and r-TEG® were more sensitive than RSCTs and the r-TEG® <math>\alpha</math>-angle was the parameter with the greatest sensitivity (84%) and validity (77%) at a cut-off of 74.7 degrees. When the r-TEG® <math>\alpha</math>-angle was combined with HR &gt;75 bpm, or hematocrit &lt; 41%, sensitivity (84%, 88%) and specificity (75%, 73%) were improved. Cut-off points for transfusion can be determined with r-TEG® <math>\alpha</math> angle and can provide better sensitivity than RSCTs.</li> <li>3. None</li> </ol>
Kashuk 2012 [37]	<ol style="list-style-type: none"> <li>1. INR at 6 h did not discriminate between survivors and non survivors (<math>p = .10</math>).</li> <li>2. In r-TEG®-guided transfusion, patients with a MRTG &gt; 9.2 received significantly less components of RBCs, FFP, and Cryo (<math>p = .048</math>, <math>p = .03</math>, and <math>p = .04</math>, respectively)</li> <li>3. r-TEG® G value was associated with survival as was MRTG and TG (<math>p = .03</math>).</li> </ol>
Kunio 2012 [62]	<ol style="list-style-type: none"> <li>1. None</li> <li>2. None</li> <li>3. In TBI patients, prolonged R time (&gt;9 min) or reduced MA (&lt;55 mm) as evaluated by TEG®, are associated with greater mortality (50% vs. 11.7% and 33.3% vs. 9.8%, respectively; <math>p = .04</math>).</li> </ol>
Kutcher 2012 [38]	<ol style="list-style-type: none"> <li>1. Patients with HF diagnosed by ROTEM® had lower T°C, pH, PLT count and higher INR, aPTT and D-dimer. The presence of hypothermia (temperature &lt; 36.0°C), acidosis (pH &lt; 7.2), relative coagulopathy (INR &gt; 1.3 or aPTT &gt; 30), or relative low PLT count (&lt;200) identified HF by ROTEM® with 100% sensitivity and 55.4% specificity (AUC, 0.77).</li> <li>2. None</li> <li>3. HF as detected by ROTEM® was associated with MODS (63.2% vs. 24.6%, <math>p = .004</math>) and mortality (52.2% vs. 12.9%, <math>p &lt; .001</math>).</li> </ol>

**Table 5 Main findings of the included studies (Continued)**

Nascimento 2012 [39]	<ol style="list-style-type: none"><li>1. For detection of coagulopathy, overall, TEG<sup>®</sup>-R performed worse than INR. TEG<sup>®</sup>-R had a sensitivity of 33% (95% CI, 16%-55%), specificity of 95% (95% CI, 91%-98%), PPV of 47% (95% CI, 23%-72%), and NPV of 92% (95% CI, 87%-95%). An INR of 1.5 or greater had a sensitivity of 67% (95% CI, 45%-84%), specificity of 98% (95% CI, 96%-99.7%), PPV of 84% (95% CI, 60%-97%), and NPV of 96% (95% CI, 92%-98%). An INR of 1.3 or greater also had better sensitivity, PPV, and NPV, than TEG<sup>®</sup>.</li><li>2. None</li><li>3. None</li></ol>
Ostrowski 2012 [53]	<ol style="list-style-type: none"><li>1. None</li><li>2. Patients considered coagulopathic ("endogenous heparinization") based on TEG<sup>®</sup> parameters (R, K, <math>\alpha</math>-angle and MA) received more RBC (10 vs. 0), FFP (7 vs. 0) and platelet (3 vs. 0) in the first 24 hours (<math>p &lt; .05</math>).</li><li>3. These patients showed a tendency towards higher 30-day mortality (50% vs. 16%, <math>p = .15</math>).</li></ol>
Pezold 2012 [54]	<ol style="list-style-type: none"><li>1. None</li><li>2. INR, ISS, and G were predictors of MT. The predictive power for outcome MT did not differ among INR (adjusted AUC ROC = .92), aPTT (AUC ROC = .90, <math>p = .41</math>), or G (AUC ROC = .89, <math>p = .39</math>).</li><li>3. 21% of patients died of MT-related complications. Age, ISS, SBP, and G were associated with MT-death. For outcome MT-death, G had the greatest adjusted AUC ROC (0.93) compared with the AUC ROC for BD (0.87, <math>p = .05</math>), INR (0.88, <math>p = .11</math>), and PTT (0.89; <math>p = .19</math>).</li></ol>
Raza 2013 [55]	<ol style="list-style-type: none"><li>1. None</li><li>2. Patients with moderate and severe fibrinolytic activity, based on plasmin-antiplasmin complex levels and ROTEM<sup>®</sup> ML &gt; 15%, required more transfusions: RBC (2.0 and 6.5 units, respectively), FFP (1 and 2.9 units, respectively), platelets (0.2 and 0.7 units, respectively) and cryoprecipitate (0.2 and 0.6 units, respectively) (<math>p &lt; .05</math> for all comparisons).</li><li>3. Similarly, patients with moderate and severe fibrinolytic activity, had significantly greater 28-day mortality (12.1% and 40% respectively, <math>p &lt; .05</math>).</li></ol>
Rourke 2012 [40]	<ol style="list-style-type: none"><li>1. ROTEM<sup>®</sup> parameters correlated with fibrinogen level, and ex vivo fibrinogen administration reversed coagulopathy by ROTEM<sup>®</sup></li><li>2. None</li><li>3. Fibrinogen level was an independent predictor of mortality at 24 h and 28 days (<math>p &lt; .001</math>). Hypofibrinogenemia can be detected early by ROTEM<sup>®</sup> and administration of cryo or fibrinogen concentrate can improve survival.</li></ol>
Wohlauer 2012 [41]	<ol style="list-style-type: none"><li>1. In trauma patients, median ADP inhibition of platelet function was 86.1% vs. 4.2% and impaired platelet function in response to AA was 44.9% vs. 0.5% when compared to healthy volunteers (<math>p &lt; .0001</math>).</li><li>2. ADP inhibition correlated with the RBC transfusion within the first 6 hours, 59.6% (0 RBC) vs. 96.1% (&gt;1 RBC) (Wilcoxon <math>p = .025</math>).</li><li>3. None.</li></ol>
Woolley 2013 [42]	<ol style="list-style-type: none"><li>1. 51% of all 48 patients were coagulopathic. EXTEM MCF &lt; 40 mm and interim EXTEM A5 and A10 predicted coagulopathy with sensitivities/specificities of 96%/58% (A5) and 100%/ 70% (A10). In addition, statistical comparison of clotting domains between normal volunteers and trauma patients suggests a difference in clot strengths due to a difference in PLT function rather than PLT number (mean 142,000/mm<sup>3</sup>).</li><li>2. None</li><li>3. None</li></ol>
Chapman 2013 [43]	<ol style="list-style-type: none"><li>1. Both G and MA values initially normal, crossed to the hypercoagulable range at 48 hours. G values rose from 7.4 ± 0.5 Kd/cs to 15.1 ± 1.9 Kd/cs (<math>p &lt; .01</math>), and MA from 57.6 mm to 74.5 mm (<math>p = .01</math>).</li><li>2. None</li><li>3. None</li></ol>
Chapman 2013 [56]	<ol style="list-style-type: none"><li>1. None</li><li>2. In the general trauma population, LY30 of greater than 3% was associated with MT in 16.7% of the patients vs. 2.1% of those with LY30 &lt; 3% (<math>p = .006</math>).</li><li>3. Similarly, LY30 ≥ 3% was associated with all-cause mortality of 20.8% vs. 4.7% (<math>p = .011</math>).</li></ol>
Harr 2013 [44]	<ol style="list-style-type: none"><li>1. Functional Fibrinogen Levels (FF) significantly correlated with von Clauss fibrinogen levels (<math>R^2 = 0.87</math>) and MA (<math>R^2 = 0.80</math>). The mean fibrinogen contribution to MA was 30%; however, there was a direct linear relationship with fibrinogen level and % fibrinogen contribution to MA (<math>R^2 = 0.83</math>). The addition of fibrinogen concentrate in <i>in vitro</i> studies increased MA (60.44 ± 1.48 to 68.12 ± 1.39) and % fibrinogen contribution to MA (23.8 ± 1.8% to 37.7 ± 2.5%).</li><li>2. None</li><li>3. None</li></ol>

**Table 5 Main findings of the included studies (Continued)**

Johansson 2013 [45]	<ol style="list-style-type: none"> <li>1. TEG<sup>®</sup> FF MA and G were lower in the hypocoagulable and significantly higher in hypercoagulable patients compared to patients with normal kaolin TEG<sup>®</sup> MA. By r-TEG<sup>®</sup>, R time, angle, MA, and G were reduced in hypocoagulable patients. LY30 was significantly increased in hypocoagulable patients by both TEG<sup>®</sup> and r-TEG<sup>®</sup></li> <li>2. Of the investigated TEG<sup>®</sup>, FF, and r-TEG<sup>®</sup> variables, MA, G, and LY30 were univariate predictors of MT whereas none were independent predictors of MT at 6 or 24 h</li> <li>3. Nonsurvivors had significantly lower TEG<sup>®</sup> MA and lower FF MA and G compared to survivors. Further, r-TEG<sup>®</sup> angle and LY30 were lower in nonsurvivors.</li> </ol>
Lee 2013 [46]	<ol style="list-style-type: none"> <li>1. There was a strong correlation between the r-TEG<sup>®</sup> and TEG<sup>®</sup> MA, which represents platelet function (R = .80). There was a moderate correlation between the G (R = .70) the overall clot strength, k (R = .66) speed of clot formation, and <math>\alpha</math>-angle (R = .38), which reflects the degree of fibrin cross-linking. Lysis at 30 minutes correlated poorly (R = .19).</li> <li>2. None</li> <li>3. None</li> </ol>
Tapia 2013 [63]	<ol style="list-style-type: none"> <li>1. None</li> <li>2. None</li> <li>3. TEG<sup>®</sup>-directed resuscitation is superior to MTP in MT penetrating trauma receiving <math>\geq 10</math>U RBC. TEG<sup>®</sup>-directed resuscitation is equivalent to standardized MTP for all patients receiving <math>\geq 6</math>U RBC and is also equivalent to standardized MTP for blunt trauma receiving <math>\geq 10</math>U RBC. MTP worsened mortality in penetrating trauma receiving <math>\geq 10</math>U RBC, indicating a continued need for TEG<sup>®</sup>-directed therapy.</li> </ol>
Kornblith 2014 [47]	<ol style="list-style-type: none"> <li>1. Coagulopathic patients (INR <math>\geq 1.3</math>) had lower admission MA FF than non-coagulopathic patients (24.7% vs. 31.2%, <math>p &lt; .05</math>). %MA PLT was higher than MA FF at all-time points, decreased over time, and stabilized at 72 h (69.4% at 0 h, 56.2% at 72 h). In contrast, MA FF increased over time and stabilized at 72 hours (30.6% at 0 h, 43.8% at 72 h).</li> <li>2. Patients requiring FFP had a significantly lower admission MA FF (26.6% vs. 30.6%, <math>p &lt; .05</math>).</li> <li>3. Higher admission MA FF was predictive of reduced mortality (hazard ratio, 0.815, <math>p &lt; .001</math>).</li> </ol>
Branco 2014 [48]	<ol style="list-style-type: none"> <li>1. 26.3% were hypercoagulable, 55.9% had a normal TEG<sup>®</sup> profile, and 17.8% were hypocoagulable.</li> <li>2. After adjustment, hypercoagulable patients were less likely to require uncross-matched blood (adjusted <math>p = .004</math>) and less total blood products, in particular, plasma at 6 h (adjusted <math>p &lt; .001</math>) and 24 h (adjusted <math>p &lt; .001</math>).</li> <li>3. Hypercoagulable patients had lower 24 h mortality (0.0% vs. 5.5% vs. 27.8%, adjusted <math>p &lt; .001</math>) and 7-day mortality (0.0% vs. 5.5% vs. 36.1%, adjusted <math>p &lt; .001</math>). Bleeding-related deaths were less likely in the hypercoagulable group (0.0% vs. 1.8% vs. 25.0%, adjusted <math>p &lt; .001</math>).</li> </ol>

Table legend: A10 – clot amplitude at 10 minutes, A15 – clot amplitude at 15 minutes, AA – arachidonic acid, ACT – activated clotting time, ADP – adenosine diphosphate, ANOVA – analysis of variance,  $\alpha$  angle – rate of clot formation, aPTT – activated partial thromboplastin time, AT – antithrombin, ATC – acute trauma coagulopathy, AUC – area under the curve, BD – base deficit, BE – base excess, BP – blood pressure, CFT – clot formation time, CI – confidence interval, CLI – clot lysis index, CT – clotting time, ED – emergency department, ELT – euglobin lysis time, EXTEM – extrinsically-activated test with tissue factor, F 1 + 2 – prothrombin fragment 1 + 2, FF – functional fibrinogen test, FFP – fresh frozen plasma, FIBTEM – fibrin-based extrinsically activated test with tissue factor and the platelet inhibitor cytochalasin D, G – shear elastic modulus strength ([5000 – MCF] / [100 – MCF] in ROTEM<sup>®</sup> and [5000 – MA] / [100 – MA] in TEG<sup>®</sup>), HCR – hemostatic control resuscitation, HF – hyperfibrinolysis, INTEM – intrinsically-activated test using ellagic acid, INR – international normalized ratio, ISS – injury severity score, K – kinetic time (time between 2 and 20 mm amplitude achieved in TEG<sup>®</sup>), LR – logistic regression, LY30 – percent decrease in clot amplitude at 30 min after MA in TEG<sup>®</sup>, MA – maximal amplitude, MCF – maximal clot firmness, ML – maximum lysis, MODS – multiple organ dysfunction syndrome, MRTG – maximum rate of thrombin formation, MT – massive transfusion, NPV – negative predictive value, OR – operating room, PE – pulmonary embolism, PCC – prothrombin complex concentrate, PF – primary fibrinolysis, PLT – platelet concentrate, PM – platelet mapping, PPV – positive predictive value, PT – prothrombin time, R – mean time for clot formation, RBC – red blood cells, RISC – revised injury severity classification, ROC – receiver operating curve, RSCT – routine screening coagulation tests, RTS – revised trauma score, SBP – systolic blood pressure, TAT – thrombin antithrombin complex, TBI – traumatic brain injury, TE – thromboembolic event, TEG<sup>®</sup>-PM – TEG<sup>®</sup> platelet mapping, TEM – thromboelastometry, TNF- $\alpha$  – tumor necrosis factor alpha, t-PA – tissue plasminogen activator, TRISS – trauma injury severity score.

after MA) of 3% or greater had poor sensitivity (31%) but high specificity (91%) for predicting MT [56].

Investigators have also compared TEG<sup>®</sup>/ROTEM<sup>®</sup> with RCST for prediction of any blood-product transfusion, generally guided by RSCT or a massive transfusion protocol (MTP). One study [52] found that r-TEG<sup>®</sup>  $\alpha$ -angle <74.7 degrees had higher sensitivity (84%) but lower specificity (57%) to predict transfusion of any blood product versus INR >1.2 (38%, 88%), INR >1.5 (19%, 96%), or aPTT >60 (5%, 98%); fibrinogen <3 g/L had the highest sensitivity (90%) and similar specificity (48%). Another study [26] showed a similar pattern for ROTEM<sup>®</sup> A5  $\leq$  35 mm in

prediction of any RBC (sensitivity 33%, specificity 88%) or FFP (36%, 87%) compared with INR >1.2 (17%, 96% for RBC; 21%, 96% for FFP).

Considered in isolation, many TEG<sup>®</sup>/ROTEM<sup>®</sup> abnormalities have been associated with transfusion of specific blood products. Reduced TEG<sup>®</sup> MA was associated with transfusion of RBC [15,29], FFP [29], and PLT [29]; TEG<sup>®</sup> ACT predicted RBC, FFP, and PLT transfusions within the first 2 hours [25];  $\alpha$ -angle <56 predicted MT of RBC, FFP, PLT, and cryoprecipitate [35]; and patients with r-TEG<sup>®</sup>-defined maximum rate of thrombin generation (MRTG)  $\geq 9.2$  mm/min at 3 hours received

significantly less RBC, FFP, and cryoprecipitate in the first 6 hours [37]. A study combining several markers [53] showed that patients considered coagulopathic based on TEG<sup>®</sup> (R, K,  $\alpha$ -angle, and MA) received more RBC (10 versus 0), FFP (7 versus 0), and PLT (3 versus 0) in the first 24 hours ( $P < 0.05$ ). More recently, the inhibition of ADP function was correlated with transfusion in the first 6 hours (59.6% inhibition (0 RBC) versus 96.1% inhibition ( $>1$  RBC),  $P = .025$ ) [41], and TEG<sup>®</sup>-defined hypocoagulable patients required more uncross-matched blood (adjusted  $P = 0.004$ ) and FFP (adjusted  $P < 0.001$ ) at 24 hours compared with normocoagulable and hypercoagulable patients [48].

Finally, patients requiring FFP had a significantly lower admission fibrinogen contribution to MA by the FF assay (26.6% versus 30.6%;  $P < 0.05$ ). In contrast, one study [16] showed no significant differences in TEG<sup>®</sup> parameters (R, K,  $\alpha$ -angle, MA, LY60 (percentage decrease in clot amplitude at 60 minutes after MA) in patients transfused with RBC, FFP, or PLT versus not; only MA-ADP, a measure of ADP-platelet activation, correlated with transfusion of any blood product ( $P = 0.004$ ).

Similarly, nonsurviving patients with isolated TBI had more ROTEM<sup>®</sup>-defined coagulation abnormalities and received more RBCs ( $P = 0.016$ ), FC ( $P = 0.01$ ) and PCC ( $P < 0.001$ ) than survivors [23], and higher FIBTEM MCF was associated with decreased RBC transfusion (adjusted OR, 0.92 per 1-unit increase, 95% CI, 0.87 to 0.98) [32]. Patients with HF [55], based on plasmin-antiplasmin complex levels and ROTEM<sup>®</sup> maximum lysis (ML)  $>15\%$ , required more transfusions of RBC, FFP, PLT, and cryoprecipitate ( $P < 0.05$  for all comparisons).

Few data exist on TEG<sup>®</sup>/ROTEM<sup>®</sup> to monitor coagulopathy in response to transfusion. Rourke *et al.* [40] showed that administration of high doses of FC (6 to 12 g) or cryoprecipitate (30 U) restored EXTEM and FIBTEM A5 and MCF to the level of patients with minor injuries; fibrinogen levels were maintained but not augmented after FC administration. Changes in ROTEM<sup>®</sup>-determined CT, A5, and MCF after the transfusion of 4 units of RBC, dependent on the RBC/FFP ratio ( $\geq 1:1$ ,  $1:2$  to  $3:4$ ,  $<1:2$ ) [50].

**TEG<sup>®</sup>/ROTEM<sup>®</sup>-guided transfusions versus conventional guidance** A modeling study [49] ( $n = 44$ ) suggested that transfusion guided by r-TEG<sup>®</sup> versus RSCT would reduce the proportion of patients needing blood-product transfusion from 73.1% to 53.9% ( $P = 0.03$ ), driven by reductions in FFP administration (61.5% with INR trigger versus 26.9% with r-TEG<sup>®</sup>-ACT trigger,  $P = 0.003$ ). No difference was predicted for transfusion of PLT ( $P = 0.32$ ) or cryoprecipitate ( $P = 0.18$ ). A cohort study reported lower exposure to blood products in 80 patients with ROTEM<sup>®</sup>-guided FC and PCC compared with a

historical group ( $n = 601$ ) for whom FFP and PLT transfusions were guided by clinical decision (generally RSCT) [51]. Transfusion of RBC (PLT) was avoided in 29% (91%) of patients in the ROTEM<sup>®</sup>-guided FC and PCC group compared with 3% (56%) in the RSCT-guided FFP and PLT groups ( $P < 0.001$ ).

### Mortality

**Prediction** TEG<sup>®</sup> and ROTEM<sup>®</sup> parameters have been compared with RCSTs for prediction of mortality. For prediction of coagulopathy-related death, G had a similar adjusted AUC (0.93, 95% CI, 0.87 to 0.98) compared with INR (AUC, 0.88; 95% CI, 0.80 to 0.97;  $P = 0.11$ ) and aPTT (AUC, 0.89; 95% CI, 0.81 to 0.97;  $P = 0.19$ ) [54]. In another analysis, r-TEG<sup>®</sup> G, MRTG, and total thrombin generation (TG) ( $P = 0.03$  for each) discriminated between survivors and nonsurvivors, in contrast to INR at 6 hours ( $P = 0.10$ ) [37]. Another study found that TEG<sup>®</sup>-defined hypercoagulable patients had lower 24-hour mortality (0 versus 5.5% (normocoagulable) versus 27.8% (hypocoagulable), 10 deaths total, adjusted  $P < 0.001$ ) and hospital mortality (11.1% versus 5.5% versus 38.9%, 20 deaths total, adjusted  $P < 0.001$ ) [48]. With ROTEM<sup>®</sup>, a study [23] showed similar discrimination for mortality in TBI by using EXTEM with cytochalasin D (FIBTEM) MCF (AUC, 0.77; 95% CI, 0.66 to 0.85) and aPTT (AUC, 0.79; 95% CI, 0.69 to 0.87). A second study ( $n = 334$ ; 26 early deaths) [32] using RSCTs, ROTEM<sup>®</sup>, and clinical judgment to guide transfusion, demonstrated significant correlations among PT, aPTT, fibrinogen, platelet count, and ROTEM<sup>®</sup> measurements (all | Spearman  $r$  |  $>0.5$ ). In separate logistic regression analyses, each adjusted for hemoglobin and base excess, PT, aPTT, CT, CFT, MCF, LI (all EXTEM) and FIBTEM MCF were associated with 24-hour mortality. However, the predictive abilities of ROTEM<sup>®</sup> measurements and RSCTs were not directly compared.

Considering TEG<sup>®</sup>/ROTEM<sup>®</sup> measurements alone, weak clot strength [16,21,29,32,37,45,47,54,57,58,61,62] and HF [14,16,21,23,32,33,35,36,38,40,45,55,56,60] have been associated with morbidity and mortality. For example, ROTEM<sup>®</sup>-defined HF was associated with multiorgan dysfunction syndrome (MODS) ( $n = 115$ ; 63.2% in patients with HF versus 24.6% in patients without HF,  $P = 0.004$ ) [38] and hospital mortality ( $n = 115$ ; 52.2% versus 12.9%,  $P < 0.001$ ) [38]; five of five versus nine of 82,  $P < 0.05$  [14]). Similarly in another study [36], TEG<sup>®</sup>-defined HF (estimated percentage lysis  $>15\%$ ) was associated with increased 24-hour mortality (69.2% versus 1.9% without HF; adjusted OR, 55.8; 95% CI, 7.2 to 432.3), but the number of deaths ( $n = 12$ ) was extremely small. Holcomb [35] showed that r-TEG<sup>®</sup> LY-30, along with most other r-TEG<sup>®</sup> parameters, was associated with mortality; the logistic regression models were not

described. More recently, a study [47] examined associations of the FF assay with mortality and demonstrated that a higher admission contribution of FF to MA predicted lower mortality (unadjusted hazard ratio, 0.815;  $P < 0.001$ ; 95% CI and adjusted model not reported).

**Effect of TEG<sup>®</sup>/ROTEM<sup>®</sup>-guided transfusion** Several observational studies have examined whether TEG<sup>®</sup>/ROTEM<sup>®</sup>-guided transfusion reduced mortality after trauma and found no consistent effect. A small before/after study ( $n = 68$ ) found lower crude mortality in patients in whom resuscitation was guided by r-TEG<sup>®</sup> (29% versus 65%) but did not report statistical testing or an adjusted analysis [37]. In a retrospective cohort study of massively bleeding patients ( $n = 131$ ) transfused FC, PLT, and PCC using ROTEM<sup>®</sup> guidance, the observed mortality was 24.4%, which was lower than the expected mortality by TRISS (33.7%;  $P = 0.032$ ) but similar to expected mortality by RISC (28.7%,  $P > 0.05$ ) [59]. Similarly, another cohort study of trauma patients ( $n = 681$ ) found no difference in mortality between those treated in one center with ROTEM<sup>®</sup>-guided administration of FC and PCC (7.5%) and a multicenter control group treated with plasma transfusion (10%,  $P = 0.69$ ) guided by the usual RSCT-guided clinical practice [51]. A before/after study [63] ( $n = 289$ ) compared outcomes in trauma patients transfused with at least 6 U RBC in the first 24 hours according to TEG<sup>®</sup>-driven practice to a later period when a MTP not guided by TEG<sup>®</sup> was used. Overall, unadjusted mortality was unchanged, and MTP versus TEG<sup>®</sup>-directed care was not associated with mortality in multivariable analysis.

## Discussion

### Main findings

Our systematic review found 55 studies of TEG<sup>®</sup>/ROTEM<sup>®</sup> examining the diagnosis of trauma coagulopathies, including hypocoagulation, hypercoagulation, platelet dysfunction and fibrinolysis; guidance of blood-product administration; and associations with mortality. To our knowledge, this review is the first to summarize the literature on the use of TEG<sup>®</sup> and ROTEM<sup>®</sup> in trauma. The overall methodologic quality of included studies was moderate. No RCTs were reported; most cohort studies lacked clinically similar control groups managed without TEG<sup>®</sup>/ROTEM<sup>®</sup>, and standard measures of diagnostic accuracy were inconsistently reported. Observational data suggest that TEG<sup>®</sup> and ROTEM<sup>®</sup> may have adequate diagnostic properties for abnormalities identified by RSCTs and may identify additional coagulation disorders. However, the effect of these tests on the need for blood-product transfusion and mortality is unclear.

Studies in different but related clinical settings, not included in this systematic review, have also investigated

TEG<sup>®</sup> and ROTEM<sup>®</sup>. Two studies of ROTEM<sup>®</sup> in a mixed population with shock [66] and noncardiac surgery [67] demonstrated rapid and useful results to guide decisions in hemostatic resuscitation. Other studies with mixed trauma and nontrauma populations [68-71] demonstrated good ability of ROTEM<sup>®</sup> to predict the need for MT, a clinically useful outcome regardless of management approach (laboratory abnormality-directed versus blood-product ratio based). Another possible advantage of these tests is that timely results may avoid FFP transfusion and subsequent FFP-related adverse events. However, relevant RCTs to test these hypotheses are lacking.

Other randomized [72-74] and observational [75-77] studies in cardiac surgery, burns, and mixed perioperative settings found reduced blood product transfusion and improved clinical outcomes after implementation of POC coagulation-management algorithms guided by ROTEM<sup>®</sup>. In contrast, existing observational studies in trauma patients do not suggest an effect of TEG<sup>®</sup>/ROTEM<sup>®</sup>-based transfusion protocols on clinically important outcomes, including mortality.

### Strengths and weaknesses of this study

Major limitations of this review are related to the quality of the included studies. Reproducible technical standards for the performance of TEG<sup>®</sup>/ROTEM<sup>®</sup> were lacking, and inconsistent reporting of  $2 \times 2$  tables precluded calculation of summary diagnostic test-performance measures and exploration of threshold effects. A major problem faced by diagnostic studies of trauma coagulopathy is the ambiguous nature of the gold standard, given that RSCTs may not provide an adequate description of all associated abnormalities. No RCTs exist in trauma patients, aside from one that enrolled burns patients exclusively [73], and the quality of the observational studies is modest. Studies differed in the use of TEG<sup>®</sup> or ROTEM<sup>®</sup>, and the few studies [78,79] that compared TEG<sup>®</sup> and ROTEM<sup>®</sup> concluded that these methods are not interchangeable.

Studies also examined different patient populations, transfusion triggers, and transfusion protocols, limiting direct comparisons and generalizability. Clinical differences between many included studies and contemporary practice include substitution of FFP for clotting factors concentrate such as PCC, FC, and cryoprecipitate. Other methods for analysis of platelet dysfunction have been developed, such as platelet function analyzer (PFA-100) and multiple platelet function analyzer (Multiplate). These analyzers monitor different aspects of platelet function and appear to be technically reliable and practical POC devices, despite limitations [65,80-82].

Two systematic reviews of TEG<sup>®</sup>/ROTEM<sup>®</sup> exist for nontrauma populations. A Cochrane review [83] included nine RCTs, mostly in cardiac surgery, that compared

transfusion guided by TEG<sup>®</sup>/ROTEM<sup>®</sup> with transfusion guided by clinical judgment, RSCTs, or both in severely bleeding patients. The review found that TEG<sup>®</sup>/ROTEM<sup>®</sup> reduced blood loss by a mean of 85 ml (95% CI, 29 to 141 ml) but had no effect on mortality.

Another systematic review [84] included 16 observational studies and two RCTs in patients with sepsis and concluded that TEG<sup>®</sup>/ROTEM<sup>®</sup> (compared with RSCTs) detect impaired fibrinolysis, which may help to discriminate between sepsis and systemic inflammatory response syndrome (SIRS). However, limitations of data prevented conclusions regarding the value of TEG<sup>®</sup>/ROTEM<sup>®</sup> to identify patients with sepsis who could benefit from anticoagulants.

## Conclusions

In summary, our systematic review demonstrated limited but rapidly growing observational evidence on the use of TEG<sup>®</sup> and ROTEM<sup>®</sup> in trauma. Both methods may be useful for diagnosis of early trauma coagulopathies, specifically hypocoagulability, hypercoagulability, hyperfibrinolysis, and platelet dysfunction. They may also be used to direct blood and blood-product transfusion; effects on patient-important outcomes are uncertain. The existing literature helps clinicians to appreciate the potential impact of these novel methods on transfusion guidance and outcomes in trauma. However, adequately powered and methodologically sound RCTs will be required to prove positive effects on blood-product transfusion and patient-important outcomes.

## Key messages

- The literature on TEG<sup>®</sup> and ROTEM<sup>®</sup> in trauma is limited by the lack of randomized controlled trials and the moderate quality of observational studies.
- TEG<sup>®</sup> and ROTEM<sup>®</sup> may be superior to routine screening coagulation tests to promptly diagnose early trauma coagulopathy, including hypocoagulability, hyperfibrinolysis, hypercoagulability, and platelet dysfunction.
- Many TEG<sup>®</sup> and ROTEM<sup>®</sup> abnormalities predict the need for massive transfusion and predict death, but predictive performance is not consistently superior to routine screening coagulation tests.
- Limited evidence from one observational study suggests that a ROTEM<sup>®</sup>-based transfusion algorithm reduces the amount of blood and blood products transfused.
- TEG<sup>®</sup> and ROTEM<sup>®</sup>-based resuscitation for bleeding trauma patients is not associated with lower mortality in most observational studies, but the question requires evaluation in randomized trials.

## Additional file

**Additional file 1: Details of literature search methods and references for the excluded studies.**

## Abbreviations

A10: Clot amplitude at 10 minutes; A15: clot amplitude at 15 minutes; A5: clot amplitude at 5 minutes after CT (in ROTEM<sup>®</sup>); AA: arachidonic acid; ACT: activated clotting time; ADP: adenosine diphosphate; aPTT: activated partial thromboplastin time; AT: antithrombin; ATC: acute trauma coagulopathy; AUC: area under the curve; BD: base deficit; BE: base excess; BP: blood pressure; CFT: clot-formation time; CI: confidence interval; CLI: clot lysis index (residual clot firmness in percentage of MCF at a certain time after CT); CT: clotting time; ED: emergency department; ELT: euglobulin lysis time; EXTEM: extrinsically activated test with tissue factor; F 1 + 2: prothrombin fragment 1 + 2; FF: functional fibrinogen test; FFP: fresh frozen plasma; FIBTEM: fibrin-based extrinsically activated test with tissue factor and the platelet inhibitor cytochalasin D; G: shear elastic modulus strength [(5,000 – MA)/(100 – MA)]; HCR: hemostatic control resuscitation; HF: hyperfibrinolysis; INR: international normalized ratio; INTEM: intrinsically activated test using ellagic acid; IQR: interquartile range; ISS: injury severity score; K: kinetic time (time between 2 and 20 mm amplitude achieved in TEG<sup>®</sup>); LI30: lysis index (residual clot firmness in percentage of MCF) 30 minutes after CT in ROTEM<sup>®</sup>; LI60: lysis index (residual clot firmness in percentage of MCF) 60 minutes after CT in ROTEM<sup>®</sup>; LR: logistic regression; LY30: percentage decrease in clot amplitude at 30 minutes after MA in TEG<sup>®</sup>; LY60: percentage decrease in clot amplitude at 60 minutes after MA in TEG<sup>®</sup>; MA: maximal amplitude; MCF: maximal clot firmness; ML: maximal lysis; MODS: multiple organ-dysfunction syndrome; MRTG: maximal rate of thrombin formation; MT: massive transfusion; NOS: Newcastle-Ottawa scale; NPV: negative predictive value; OR: odds ratio; PCC: prothrombin complex concentrate; PE: pulmonary embolism; PF: primary fibrinolysis; PFA-100: platelet-function analyzer; PLT: platelet concentrate; PM: platelet mapping; POC: point-of-care; PPV: positive predictive value; PRISMA: preferred reporting items for systematic reviews and meta-analyses; PT: prothrombin time; QUADAS: quality assessment of diagnostic accuracy studies; R: reaction time (time from starting the test until 2-mm amplitude can be detected in TEG<sup>®</sup>); RBC: red blood cell; RCT: randomized controlled trial; RISC: revised injury severity classification; ROC: receiver operating curve; ROTEM<sup>®</sup>: rotational thromboelastometry; RSCT: routine screening coagulation test; r-TEG<sup>®</sup>: rapid thromboelastography; RTS: revised trauma score; SBP: systolic blood pressure; SD: standard deviation; SIRS: systemic inflammatory response syndrome; TAT: thrombin-antithrombin complex; TBI: traumatic brain injury; TE: thromboembolic event; TEG<sup>®</sup>: thromboelastography; TEG<sup>®</sup>-PM: TEG<sup>®</sup> platelet mapping; TF: tissue factor; TG: thrombin generation; TNF- $\alpha$ : tumor necrosis factor alpha; TRISS: trauma injury severity score;  $\alpha$  angle: rate of clot formation.

## Competing interests

Dr. Rizoli is a member of a Scientific Advisory Board to CSL Behring, manufacturer of fibrinogen concentrate. He is also the recipient of a Canadian Institute of Health Research (CIHR) New Investigator award in partnership with NovoNordisk Canada, manufacturer of NovoSeven (recombinant factor VII).

## Authors' contributions

LTL participated in the study design, data collection, data analysis, drafting of the manuscript, and revision of the manuscript. BN participated in the study design and manuscript revision. AKS participated in data collection and data analysis. SR participated in study design and manuscript revision. NKJA participated in the study design, data collection, data analysis, drafting of the manuscript, and revision of the manuscript. All authors approved the final manuscript.

## Acknowledgements

We thank Mr. Henry Lam for assistance with the search strategy, Michelle Hayes for retrieval of the full text of some studies, and Maria Chiu for assistance with translation. This study received no funding. Bartolomeu Nascimento was the 2010 to 2011 National Blood Foundation Grant recipient for the conduct of research related to coagulopathy in trauma.

#### Author details

<sup>1</sup>Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and University of Toronto, 2075 Bayview Avenue Room D1.08, Toronto, ON M4N 3M5, Canada. <sup>2</sup>Department of Surgery, Sunnybrook Health Sciences Centre and University of Toronto, 2075 Bayview Avenue Room H1.89, Toronto, ON M4N 3M5, Canada. <sup>3</sup>Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes, 3900, 9º andar do Hospital das Clínicas de Ribeirão Preto, Ribeirão Preto, São Paulo, Brasil. <sup>4</sup>Departments of Surgery and Critical Care Medicine, St. Michael's Hospital and University of Toronto, 30 Bond Street, 3074 Donnelly Wing, Toronto, ON M5W 1B8, Canada.

Received: 3 November 2013 Accepted: 29 August 2014

Published online: 27 September 2014

#### References

1. Chowdhury P, Saayman AG, Paulus U, Findlay GP, Collins PW: **Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients.** *Br J Haematol* 2004, **125**:69–73.
2. Lier H, Bottiger BW, Hinkelbein J, Krep H, Bernhard M: **Coagulation management in multiple trauma: a systematic review.** *Intensive Care Med* 2011, **37**:572–582.
3. Hoffman M, Monroe DM III: **A cell-based model of hemostasis.** *Thromb Haemost* 2001, **85**:958–965.
4. Da Luz LT, Nascimento B, Rizoli S: **Thrombelastography (TEG®): practical considerations on its clinical use in trauma resuscitation.** *Scand J Trauma Resusc Emerg Med* 2013, **21**:29.
5. Moher D, Liberati A, Tetzlaff J, Altman DG: **Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.** *Int J Surg* 2010, **8**:336–341.
6. Cohen J: **Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit.** *Psychol Bull* 1968, **70**:213–220.
7. **The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses** [http://www.ohri.ca/programs/clinical\_epidemiology/oxford.htm]. Accessed March 2013.
8. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM: **QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.** *Ann Intern Med* 2011, **155**:529–536.
9. Kaufmann CR, Dwyer KM, Crews JD, Dols SJ, Trask AL: **Usefulness of thrombelastography in assessment of trauma patient coagulation.** *J Trauma* 1997, **42**:716–722.
10. Watts DD, Trask A, Soeken K, Perdue P, Dols SJ, Kaufmann C: **Hypothermic coagulopathy in trauma: effect of varying levels of hypothermia on enzyme speed, platelet function, and fibrinolytic activity.** *J Trauma* 1998, **44**:846–854.
11. Schreiber MA, Differding J, Thorborg P, Mayberry JC, Mullins RJ: **Hypercoagulability is most prevalent early after injury and in female patients.** *J Trauma* 2005, **58**:475–481.
12. Rugeri L, Levrat A, David JS, Delecroix E, Floccard B, Gros A, Allaouchiche A, Negrier C: **Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography.** *J Thromb Haemost* 2007, **5**:289–295.
13. Nekdulov M, Bellander B, Blombäck M, Wallen HN: **Platelet dysfunction in patients with severe traumatic brain injury.** *J Neurotrauma* 2007, **24**:1699–1706.
14. Levrat A, Gros A, Rugeri L, Inaba K, Floccard B, Negrier C, David JS: **Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients.** *Br J Anaesth* 2008, **100**:792–797.
15. Plotkin AJ, Wade CE, Jenkins DH, Smith KA, Noe JC, Park MS, Perkins JG, Holcomb JB: **A reduction in clot formation rate and strength assessed by thrombelastography is indicative of transfusion requirements in patients with penetrating injuries.** *J Trauma* 2008, **64**:S64–S68.
16. Carroll RC, Craft RM, Langdon RJ, Clanton CR, Snider CC, Wellons DD, Dakin PA, Lawson CM, Enderson BL, Kurek SJ: **Early evaluation of acute traumatic coagulopathy by thrombelastography.** *Transl Res* 2009, **154**:34–39.
17. Jeger V, Zimmermann H, Exadaktylos AK: **Can rapidTEG® accelerate the search for coagulopathies in the patient with multiple injuries?** *J Trauma* 2009, **66**:1253–1257.
18. Kashuk JL, Moore EE, Sabel A, Barnett C, Haenel J, Le T, Pezold M, Lawrence J, Biffi WL, Cothren CC, Johnson JL: **Rapid thrombelastography (r-TEG®) identifies hypercoagulability and predicts thromboembolic events in surgical patients.** *Surgery* 2009, **146**:764–774.
19. Park MS, Martini WZ, Dubick MA, Salinas J, Butenas S, Kheirabadi BS, Pusateri AE, Vos JA, Guymon CH, Wolf SE, Mann KG, Holcomb JB: **Thrombelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time.** *J Trauma* 2009, **67**:266–276.
20. Doran CM, Woolley T, Midwinter MJ: **Feasibility of using rotational thrombelastometry to assess coagulation status of combat casualties in a deployed setting.** *J Trauma* 2010, **69**:S40–S48.
21. Kashuk JL, Moore EE, Sawyer M, Wohlauser M, Pezold M, Barnett C, Biffi WL, Burlew CC, Johnson JL, Sauaia A: **Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma.** *Ann Surg* 2010, **252**:434–444.
22. Leemann H, Lustenberger T, Talving P, Kobayashi L, Bukur M, Brenni M, Brüesch M, Spahn DR, Keel MJB: **The role of rotation thrombelastometry in early prediction of massive transfusion.** *J Trauma* 2010, **69**:1403–1409.
23. Schochl H, Solomon C, Tzaintinger S, Nienaber U, Tacacs-Tolnai A, Windhofer C, Bahrami S, Voelckel W: **Thrombelastometric (ROTEM®) findings in patients suffering from isolated severe traumatic brain injury.** *J Neurotrauma* 2011, **28**:2033–2041.
24. Watters JM, Sambasivan CN, Zink K, Kremenevskiy I, Englehart MS, Underwood SJ, Schreiber MA: **Splenectomy leads to a persistent hypercoagulable state after trauma.** *Am J Surg* 2010, **199**:646–651.
25. Cotton BA, Faz G, Hatch QM, Radwan ZA, Podbielski J, Wade C, Kozar RA, Holcomb JB: **Rapid thrombelastography delivers real-time results that predict transfusion within 1 hour of admission.** *J Trauma* 2011, **71**:407–417.
26. Davenport R, Manson J, De'Ath H, Platten S, Coates A, Allard S, Hart D, Pearce R, Pasi J, MacCallum P, Stanworth S, Brohi K: **Functional definition and characterization of acute traumatic coagulopathy.** *Crit Care Med* 2011, **39**:1–7.
27. Differding JA, Underwood SJ, Van PY, Khaki RA, Spoerke NJ, Schreiber MA: **Trauma induces a hypercoagulable state that is resistant to hypothermia as measured by thrombelastogram.** *Am J Surg* 2011, **201**:587–591.
28. Jansen JO, Luke D, Davies E, Spencer P, Kirkman E, Midwinter MJ: **Temporal changes in ROTEM®-measured coagulability of citrated blood samples from coagulopathic trauma patients.** *Injury* 2013, **44**:36–39.
29. Nystrup KB, Windeløv NA, Thomsen AB, Johansson PI: **Reduced clot strength upon admission, evaluated by thrombelastography (TEG®), in trauma patients is independently associated with increased 30-day mortality.** *Scand J Trauma Resusc Emerg Med* 2011, **19**:52.
30. Ostrowski SR, Sørensen AM, Larsen CF, Johansson PI: **Thrombelastography and biomarker profiles in acute coagulopathy of trauma: a prospective study.** *Scand J Trauma Resusc Emerg Med* 2011, **19**:64.
31. Schöchl H, Cotton B, Inaba K, Nienaber U, Fischer H, Voelckel W, Solomon C: **FIBTEM provides early prediction of massive transfusion in trauma.** *Crit Care* 2011, **15**:R265.
32. Tauber H, Innerhofer P, Breitkopf R, Westermann I, Beer R, El Attar R, Strasak A, Mittermayr M: **Prevalence and impact of abnormal ROTEM® assays in severe blunt trauma: results of the 'Diagnosis and Treatment of Trauma-Induced Coagulopathy (DIA-TRE-TIC) study'.** *Br J Anaesth* 2011, **107**:378–387.
33. Cotton BA, Harvin JA, Kostousou V, Minei KM, Radwan ZA, Schöchl H, Wade CE, Holcomb JB, Matijevic N: **Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration.** *J Trauma Acute Care Surg* 2012, **73**:365–370.
34. Cotton BA, Minei KM, Radwan ZA, Matijevic N, Pivalizza E, Podbielski J, Wade CE, Kozar RA, Holcomb JB: **Admission rapid thrombelastography predicts development of pulmonary embolism in trauma patients.** *J Trauma Acute Care Surg* 2012, **72**:1470–1477.
35. Holcomb JB, Minei KM, Scerbo ML, Radwan ZA, Wade CE, Kozar BA, Gill BS, Albarado R, McNutt MK, Khan S, Adams PR, McCarthy JJ, Cotton RA: **Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department experience with 1974 consecutive trauma patients.** *Ann Surg* 2012, **256**:476–486.
36. Ives C, Inaba K, Branco BC, Okoye O, Schöchl H, Talving P, Lam L, Shulman I, Nelson J, Demetriades D: **Hyperfibrinolysis elicited via**



- thromboelastography predicts mortality in trauma. *J Am Coll Surg* 2012, **215**:496–502.
37. Kashuk JL, Moore EE, Wohlauer M, Johnson JL, Pezold M, Lawrence T, Biffi WL, Burlew CCC, Barnett C, Sawyer M, Sauaia A: **Initial experiences with point-of-care rapid thrombelastography for management of life-threatening postinjury coagulopathy.** *Transfusion* 2012, **52**:23–33.
  38. Kutcher ME, Cripps MW, McCreery RC, Crane IM, Greenberg MD, Cachola LM, Redick BJ, Nelson MF, Cohen MJ: **Criteria for empiric treatment of hyperfibrinolysis after trauma.** *J Trauma Acute Care Surg* 2012, **73**:87–93.
  39. Nascimento B, Mahoos MA, Callum J, Capone A, Pacher J, Tien H, Rizoli S: **Vitamin K-dependent coagulation factor deficiency in trauma: a comparative analysis between international normalized ratio and thromboelastography.** *Transfusion* 2012, **2**:7–13.
  40. Rourke C, Curry N, Khan S, Taylor R, Raza I, Davenport R, Stanworth S, Brohi K: **Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes.** *J Thromb Haemost* 2012, **10**:1342–1351.
  41. Wohlauer MV, Moore EE, Thomas S, Sauaia A, Evans E, Harr J, Silliman CC, Ploplis V, Castellino FJ, Walsh M: **Early platelet dysfunction: an unrecognized role in the acute coagulopathy of trauma.** *J Am Coll Surg* 2012, **214**:739–746.
  42. Woolley T, Midwinter M, Spencer P, Watts S, Doran C, Kirkman E: **Utility of interim ROTEM® values of clot strength, A5 and A10, in predicting final assessment of coagulation status in severely injured battle patients.** *Injury* 2013, **44**:593–599.
  43. Chapman BC, Moore EE, Barnett C, Stovall RT, Biffi WL, Burlew CC, Bensard DD, Jurkovich GJ, Pieracci FM: **Hypercoagulability following blunt solid abdominal organ injury: when to initiate anticoagulation.** *Am J Surg* 2013, **206**:917–923.
  44. Harr JN, Moore EE, Ghasabyan A, Chin TL, Sauaia A, Banerjee A, Silliman CC: **Functional fibrinogen assay indicates that fibrinogen is critical in correcting abnormal clot strength following trauma.** *Shock* 2013, **39**:45–49.
  45. Johansson PI, Sørensen AM, Larsen CF, Windeløv NA, Stensballe J, Perner A, Rasmussen LS, Ostrowski SR: **Low hemorrhage-related mortality in trauma patients in a Level I trauma center employing transfusion packages and early thromboelastography-directed hemostatic resuscitation with plasma and platelets.** *Transfusion* 2013, **53**:3088–3099.
  46. Lee TH, McCully BH, Underwood SJ, Cotton BA, Cohen MJ, Schreiber MA: **Correlation of conventional thrombelastography and rapid thrombelastography in trauma.** *Am J Surg* 2013, **205**:521–527.
  47. Kornblith LZ, Kutcher ME, Redick BJ, Calfee CS, Vilardi RF, Cohen MJ: **Fibrinogen and platelet contributions to clot formation: implications for trauma resuscitation and thromboprophylaxis.** *J Trauma Acute Care Surg* 2014, **76**:255–263.
  48. Branco BC, Inaba K, Ives C, Okoye O, Shulman I, David JS, Schöchl H, Rhee P, Demetriades D: **Thromboelastogram evaluation of the impact of hypercoagulability in trauma patients.** *Shock* 2014, **41**:200–207.
  49. Kashuk JL, Moore EE, Le T, Lawrence J, Pezold M, Johnson JL, Cothren CC, Biffi WL, Barnett C, Sabel A: **Noncritrated whole blood is optimal for evaluation of postinjury coagulopathy with point-of-care rapid thromboelastography.** *J Surg Res* 2009, **156**:133–138.
  50. Davenport R, Curry N, Manson J, De'Ath H, Coates A, Rourke C, Pearse R, Stanworth S, Brohi K: **Hemostatic effects of fresh frozen plasma may be maximal at red cell ratios of 1:2.** *J Trauma* 2011, **70**:90–96.
  51. Schöchl H, Nienaber U, Maegele M, Hochleitner G, Primavesi F, Steitz B, Arndt C, Hanke A, Voelckel W, Solomon C: **Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy.** *Crit Care* 2011, **15**:R83.
  52. Jeger V, Willis S, Liu T, Yeh DD, DeMoya M, Zimmermann H, Exadaktylos AK: **The rapid TEG® α-angle may be a sensitive predictor of transfusion in moderately injured blunt trauma patients.** *Sci World J* 2012, [http://www.hindawi.com/journals/tswj/2012/821794/]
  53. Ostrowski SR, Johansson PI: **Endothelial, glycoalyx degradation induces endogenous heparinization in patients with severe injury and early traumatic coagulopathy.** *J Trauma Acute Care Surg* 2012, **73**:60–66.
  54. Pezold M, Moore EE, Wohlauer M, Sauaia A, Gonzalez E, Banerjee A, Silliman CC: **Viscoelastic clot strength predicts coagulation-related mortality within 15 minutes.** *Surgery* 2012, **151**:48–54.
  55. Raza I, Davenport R, Rourke C, Platten S, Manson J, Spoor C, Khan S, De'ATH HD, Allard S, Hart DP, Pasi KJ, Hunt BJ, Stanworth S, MacCallum PK, Brohi K: **The incidence and magnitude of fibrinolytic activation in trauma patients.** *J Thromb Haemost* 2013, **11**:307–314.
  56. Chapman MP, Moore EE, Ramos CR, Ghasabyan A, Harr JN, Chin TL, Stringham JR, Sauaia A, Silliman CC, Banerjee A: **Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy.** *J Trauma Acute Care Surg* 2013, **75**:961–967.
  57. Park MS, Salinas J, Wade CE, Wang J, Martini W, Pusateri AE, Merrill GA, Chung K, Wolf SE, Holcomb JB: **Combining early coagulation and inflammatory status improves prediction of mortality in burned and nonburned trauma patients.** *J Trauma* 2008, **64**:S188–S194.
  58. Schöchl H, Frietsch T, Pavelka M, Jambor C: **Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thromboelastometry.** *J Trauma* 2009, **67**:125–131.
  59. Schöchl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, Kozek-Langenecker S, Solomon C: **Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM®)-guided administration of fibrinogen concentrate and prothrombin complex concentrate.** *Crit Care* 2010, **14**:R55.
  60. Theusinger OM, Wanner GA, Emmert MY, Billeter A, Eismann J, Seifert B, Simmen HP, Spahn DR, Baulig W: **Hyperfibrinolysis diagnosed by rotational thromboelastometry (ROTEM®) is associated with higher mortality in patients with severe trauma.** *Anesth Analg* 2011, **113**:1003–1012.
  61. Davis PK, Musunuru H, Walsh M, Cassidy R, Yount R, Losiniecki A, Moore EE, Wohlauer MV, Howard J, Ploplis VA, Castellino FJ, Thomas SG: **Platelet dysfunction is an early marker for traumatic brain injury-induced coagulopathy.** *Neurocrit Care* 2013, **18**:201–208.
  62. Kunio NR, Differding JA, Watson KM, Stucke RS, Schreiber MA: **Thromboelastography-identified coagulopathy is associated with increased morbidity and mortality after traumatic brain injury.** *Am J Surg* 2012, **203**:584–588.
  63. Tapia NM, Chang A, Norman M, Welsh F, Scott B, Wall MJ Jr, Mattox KL, Suliburk J: **TEG®-guided resuscitation is superior to standardized MTP resuscitation in massively transfused penetrating trauma patients.** *J Trauma Acute Care Surg* 2013, **74**:378–386.
  64. Baker SP, O'Neill B, Haddon W, Long WB: **The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care.** *J Trauma* 1974, **14**:187–196.
  65. Solomon C, Trautinger S, Ziegler B, Hanke A, Rahe-Meyer N, Voelckel W, Schöchl H: **Platelet function following trauma: a multiple electrode aggregometry study.** *Thromb Haemost* 2011, **106**:322–330.
  66. Reed MJ, Nimmo AF, McGee D, Manson L, Neffendorf AE, Moir L, Donaldson LS: **Rotational thromboelastometry produces potentially clinical useful results within 10 min in bleeding emergency department patients: the DEUCE study.** *Eur J Emerg Med* 2013, **20**:160–166.
  67. Görlinger K, Dirkmann D, Solomon C, Hanke AA: **Fast interpretation of thromboelastometry in non-cardiac surgery: reliability in patients with hypo-, normo-, and hypercoagulability.** *Br J Anaesth* 2013, **110**:222–230.
  68. Inaba K, Branco BC, Rhee P, Blackburne LH, Holcomb JB, Teixeira PG, Shulman I, Nelson J, Demetriades D: **Impact of plasma transfusion in trauma patients who do not require massive transfusion.** *J Am Coll Surg* 2010, **210**:957–965.
  69. Borgman MA, Spinella PC, Holcomb JB, Blackburne LH, Wade CE, Lefering R, Bouillon B, Maegele M: **The effect of FFP:RBC ratio on morbidity and mortality in trauma patients based on transfusion prediction score.** *Vox Sang* 2011, **101**:44–54.
  70. Shanwell A, Andersson TM, Rostgaard K, Edgren G, Hjalgrim H, Norda R, Melbye M, Nyrén O, Reilly M: **Post-transfusion mortality among recipients of ABO-compatible but non-identical plasma.** *Vox Sang* 2009, **96**:316–323.
  71. Inaba K, Branco BC, Rhee P, Holcomb JB, Blackburne LH, Shulman I, Nelson J, Demetriades D: **Impact of ABO-identical vs ABO-compatible non-identical plasma transfusion in trauma patients.** *Arch Surg* 2010, **145**:899–906.
  72. Weber CF, Görlinger K, Meininger D, Herrmann E, Bingold T, Moritz A, Cohn LH, Zacharowski K: **Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients.** *Anesthesiology* 2012, **117**:531–547.
  73. Schaden E, Kimberger O, Kraincuk P, Baron DM, Metnitz PG, Kozek-Langenecker S: **Perioperative treatment algorithm for bleeding burn patients reduces allogeneic blood product requirements.** *Br J Anaesth* 2012, **109**:376–381.

74. Girdauskas E, Kempfert J, Kuntze T, Borger MA, Enders J, Fassl J, Falk V, Mohr FW: **Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial.** *J Thorac Cardiovasc Surg* 2010, **140**:1117–1124.
75. Görlinger K, Fries D, Dirkmann D, Weber CF, Hanke AA, Schöchl H: **Reduction of fresh frozen plasma requirements by perioperative point-of-care coagulation management with early calculated goal-directed therapy.** *Transfus Med Hemother* 2012, **39**:104–113.
76. Görlinger K, Dirkmann D, Hanke AA, Kamler M, Kottenberg E, Thielmann M, Jakob H, Peters J: **First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study.** *Anesthesiology* 2011, **115**:1179–1191.
77. Fassl J, Matt P, Eckstein F, Filipovic M, Gregor M, Zenklusen U, Seeberger MD, Bolliger D: **Transfusion of allogeneic blood products in proximal aortic surgery with hypothermic circulatory arrest: effect of thromboelastometry-guided transfusion management.** *J Cardiothorac Vasc Anesth* 2013, **27**:1181–1188.
78. Sankarankutty A, Nascimento B, da Luz LT, Rizoli S: **TEG® and ROTEM® in trauma: similar test but different results?** *World J Emerg Surg* 2012, **7**:S3.
79. Venema LF, Post WJ, Hendriks HG, Huet RC, de Wolf JT, de Vries AJ: **An assessment of clinical interchangeability of TEG® and ROTEM® thromboelastographic variables in cardiac surgical patients.** *Anesth Analg* 2010, **111**:339–344.
80. Kutcher ME, Redick BJ, McCreery RC, Crane IM, Greenberg MD, Cachola LM, Nelson MF, Cohen MJ: **Characterization of platelet dysfunction after trauma.** *J Trauma Acute Care Surg* 2012, **73**:13–19.
81. Görlinger K, Jambor C, Hanke AA, Dirkmann D, Adamzik M, Hartmann M, Rahe-Meyer N: **Perioperative coagulation management and control of platelet transfusion by point-of-care platelet function analysis.** *Transfus Med Hemother* 2007, **34**:396–411.
82. Adamzik M, Görlinger K, Peters J, Hartmann M: **Whole blood impedance aggregometry as a biomarker for the diagnosis and prognosis of severe sepsis.** *Crit Care* 2012, **16**:R204.
83. Afshari A, Wikkelsø A, Brok J, Møller AM, Wetterslev J: **Thrombelastography (TEG®) or thromboelastometry (ROTEM®) to monitor haemotherapy versus usual care in patients with massive transfusion.** *Cochrane Database Syst Rev* 2011, **3**, CD007871.
84. Müller MC, Meijers JCM, Vroom MB, Juffermans NP: **Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review.** *Critical Care* 2014, **18**:R30.

doi:10.1186/s13054-014-0518-9

**Cite this article as:** Da Luz et al.: Effect of thromboelastography (TEG®) and rotational thromboelastometry (ROTEM®) on diagnosis of coagulopathy, transfusion guidance and mortality in trauma: descriptive systematic review. *Critical Care* 2014 **18**:518.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

